The original disclosure in Japanese was released on May 11, 2018 at 16:00 (GMT+9)

Consolidated Financial Statements for the Year Ended March 31, 2018
FY2018(April 1, 2017 - March 31, 2018) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listing: Tokyo Stock Exchange (1st section)
Code Number: 2531
URL: http://www.takara.co.jp/
Company representative: Toshio Kakimoto, President
Contact: Takuya Kakemi, General Manager of Investor Relations Dept.
TEL : (075)241-5124

Scheduled date of general shareholders' meeting: June 28, 2018
Scheduled date of starting delivery of dividends: June 29, 2018

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the year ended March 31, 2018 (April 1, 2017 – March 31, 2018)

(1) Operating results

Note: Percentages indicated changes from the previous fiscal year.

	Year ended March 31, 2018		Year ended March 31, 2017	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	268,142	14.5	234,193	3.9
Operating income	15,612	15.2	13,551	16.0
Ordinary income	16,084	12.1	14,344	11.7
Net income (loss) attributable to owners of the parent	11,029	30.0	8,480	20.2
Net income per share (Yen)	54.97		42.15	
Fully diluted net income per share (Yen)	-		-	
Return on equity		7.9		6.4
Ordinary income to total assets ratio		5.7		5.4
Operating income to net sales ratio		5.8		5.8
Note: Comprehensive income	15,706	101.8	7,784	268.7
Reference: Income (loss) from equity method investment	83		268	

(2) Financial position

	As of March 31, 2018	As of March 31, 2017
	(Millions of yen)	(Millions of yen)
Total assets	287,059	274,368
Net assets	176,217	165,920
Equity ratio (%)	50.6	49.2
Net assets per share (Yen)	726.90	671.11
Reference: Equity	145,111	135,043

(3) Cash flow

	Year ended March 31, 2018	Year ended March 31, 2017
	(Millions of yen)	(Millions of yen)
Cash flow from operating activities	16,265	12,826
Cash flow from investing activities	(19,916)	16,200
Cash flow from financing activities	(5,570)	(2,828)
Cash and cash equivalents, end of year	49,341	58,765

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2017	Year ended March 31, 2018	Year ending March 31, 2019(Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	13.0	16.0	18.00
Annual	13.0	16.0	18.00
Total dividend (Millions of yen)	2,615	3,194	
Payout ratio (%)	30.8	29.1	37.4
Dividend on equity (%)	2.0	2.3	

3. Forecast for the year ending March 31, 2019 (April 1, 2018 – March 31, 2019)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ending September 30, 2018		Year ending March 31, 2019	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	135,000	4.8	282,000	5.2
Operating income	7,500	22.4	17,300	10.8
Ordinary income	7,800	25.8	17,900	11.3
Net income attributable to owners of the parent	4,200	21.8	9,600	(13.0)
Net income attributable to owners of the parent per share (Yen)	21.04		48.09	

4. Others

(1) Changes in subsidiaries during the period (changes in specified subsidiaries resulting in change of scope) : Yes
Newly included: 3 (Name) WaferGen Bio-systems, Inc., Rubicon Genomics, Inc., Takara Shuzo International Co., Ltd.
Excluded: 2 (Name) WaferGen Bio-systems, Inc., Rubicon Genomics, Inc.

(2) Changes in accounting policies, accounting estimates and retrospective restatement
1) Changes based on revisions of accounting standard : No
2) Changes other than ones based on revisions of accounting standard : No
3) Changes in accounting estimates : No
4) Restatement : No

(3) Number of outstanding shares (common stock)
1) Number of outstanding shares at year end (Treasury stocks are included)
As of March 31, 2018 : 201,699,743
As of March 31, 2017 : 217,699,743
2) Number of treasury stocks at year end
As of March 31, 2018 : 2,069,224
As of March 31, 2017 : 16,475,731
3) Average number of outstanding shares
Year ended March 31, 2018 : 200,632,472
Year ended March 31, 2017 : 201,224,223

Contents of the attached document

1. Overview of Financial Results---------- 2
   (1) Overview of Financial Results for the Fiscal Year under Review---------- 2
   (2) Overview of Financial Position for the Fiscal Year under Review---------- 5
   (3) Overview of Cash Flows for the Fiscal Year under Review---------- 6
   (4) Future Outlook---------- 6
2. Basic concept on selection of accounting standards---------- 7
3. Consolidated Financial Statements and Important Notes---------- 8
   (1) Consolidated Balance Sheets---------- 8
   (2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income---------- 10
      Consolidated Statements of Income---------- 10
      Consolidated Statements of Comprehensive Income---------- 11
   (3) Consolidated Statements of Changes in Net Assets---------- 12
   (4) Consolidated Statements of Cash Flows---------- 14
   (5) Notes to Consolidated Financial Statements ---------- 15
      (Notes on Premise of Going Concern) ---------- 15
      (Segment Information) ---------- 15
      (Per Share Information) ---------- 17
      (Significant Subsequent Events) ---------- 17

○ Supplement for the Consolidated Financial Statements

1.Overview of Financial Results

(1) Overview of Financial Results for the Fiscal Year under Review

In the fiscal year under review, ended March 31, 2018, although personal spending was weak, the Japanese economy maintained a moderate recovery as corporate earnings and the hiring environment improved backed by robust demand inside and outside Japan. On the other hand, overseas, while the trend of moderate recovery was expected to persist going forward, including the manufacturing industry-based expansion in the U.S. economy and the recovery in the Chinese economy, there was also continued uncertainty for the future of the global economy with the mounting concern about trade friction and the tension in East Asia and the Middle East.

Under these economic circumstances, in fiscal 2018, the Company initiated the Takara Group Medium-Term Management Plan FY2020, as the last step towards achieving its long-term Takara Group Vision 2020. By further increasing the overseas sales ratio together with having a full product line-up and many products with a competitive edge both in Japan and overseas, the Company is aiming to build up a great number of fields in which it can beat competitors and establish a balanced business foundation able to grow revenues significantly no matter what environmental changes occur.

As a result, in the fiscal year under review, ended March 31, 2018, net sales were up by 14.5% year on year to ¥268,142 million. Gross profit rose 11.3 % year on year to ¥104,612 million. Operating income increased by 15.2% year on year to ¥16,084 million while ordinary income rose 12.1% year on year to ¥15,612 million. Net income attributable to owners of the parent increased by 30.0% year on year to ¥11,029 million.

Results by business segment were as follows.

The meeting of the Company's Board of Directors held on February 16, 2017 resolved to spin off (incorporation-type company split) the overseas business of Takara Shuzo Co., Ltd., a consolidated subsidiary of the Company, and transfer it to the newly established Takara Shuzo International Co., Ltd. on July 3, 2017. As a result of reviewing its reporting segments in accordance with this, the company changed its reporting segments starting from the fiscal year under review, ended March 31, 2018, and year on year comparisons below compare the figures for the previous fiscal year reclassified into the post-change segments.

(Takara Shuzo)

The severe competitive environment is expected to continue as the decrease in total consumption of alcoholic beverages in Japan is forecast to persist in addition to the diversification of consumer preferences and an ongoing frugal mindset.

In this environment, Takara Shuzo continued to develop products differentiated by its technology in addition to strengthening its product development system in order to respond to diversifying consumer needs in a timely and prompt manner and focusing efforts on increasing competitiveness in the alcoholic beverage and seasonings categories by expanding its product range. Takara Shuzo also worked on improving its profit ratios by increasing the sales ratio of high value added products while striving to strengthen safety assurance and quality control systems for raw materials in order to supply safe and secure products as a food manufacturer.

The segment's sales and other information are as follows:

[Alcoholic beverages]

Shochu

For *ko*-type shochu, Takara Shuzo worked to expand sales of such products as *Gokujo Takara Shochu*, and *Takara Shochu for Lemon Sour*, going for a great tasting alcoholic beverage as a sour base, and *Takara Shochu Takara Modern*. For *Honkaku* shochu, Takara Shuzo worked on revitalizing the *Ikkomon* brand, which included launching *Ikkomon Akane (100% sweet-potato-base)*.

Overall shochu net sales, however, decreased 4.1% year on year to ¥55,034 million, affected by the shrinking shochu market.

Sake

For sake, Takara Shuzo worked on expanding sales of *Sho Chiku Bai Ten* for consumption at home and *Sho Chiku Bai Gokai* for the commercial market. For *Mio*, Takara Shuzo launched *Sho Chiku Bai Shirakabegura Mio WHITE Sparkling Sake*, an easy-to-drink cloudy sake which retains the great taste of Mio with a refreshing sweet and sour flavor. Takara Shuzo also strengthened its range of small and medium volume products such as *Daiginjo* and *Junmai Daiginjo* in addition to focusing on stimulating demand by through the launch of limited seasonal products such as *Tokusen Sho Chiku Bai Junmai Daiginjo Shiboritate*, featuring a freshly brewed aroma and a young juicy flavor, and *Tokusen Sho Chiku Bai Yamadanishiki Tokubetsu Junmai*.

Overall sake net sales, however, decreased 0.7% year on year to ¥22,222 million with the decline in sales of the *Sho Chiku Bai* 1.8l bottle and other products.

Light-alcohol refreshers

For light-alcohol refreshers, Takara Shuzo paid most attention to expanding sales of dry flavored chu-hi *Takara Shochu High Ball*, positioned as a flagship brand. In addition, *Takara CRAFT* launched as a new brand in the fiscal year under review is a high value added chu-hi created through the fastidious manufacturing methods that are unique to Takara Shuzo,

including the use of local materials from all over Japan and the blending of barrel-aged shochu with the base alcohol, aimed at expanding into a range of regional products that match local preferences and tastes.

Consequently, overall light-alcohol refreshers net sales increased 10.2% year on year, to ¥34,267 million.

Other alcoholic beverages

Net sales of other alcoholic beverages were down 3.8% year on year to ¥6,639 million due to a decline in sales of synthetic sake, whiskey and other products.

As a result, total alcoholic beverages net sales increased 0.3% year on year, to ¥118,163 million.

[Seasonings]

In seasonings, Takara Shuzo worked on developing and nurturing products such as those based on user needs and high value added ones differentiated by its own technology. For *Hon-Mirin*, Takara Shuzo launched *Takara Ameiro no Koku Hon Mirin* which conveniently completes Western and Chinese cuisine not to mention Japanese cuisine with a robust flavor due to its unprecedented richness and umami using proprietary manufacturing methods. Takara Shuzo also continued to focus efforts on cooking sake and worked on expanding sales of food seasonings such as fermented seasonings.

As a result, total seasonings net sales decreased 0.3% year on year to ¥23,823 million.

[Raw alcohol, etc.]

Takara Shuzo worked to expand sales of industrial alcohol and raw alcohol for alcoholic beverages. As a result, raw alcohol, etc. net sales increased 1.0% year on year to ¥7,852 million.

As a result, net sales for Takara Shuzo rose 0.3% year on year to ¥149,839 million. Cost of sales increased by 0.5% year on year to ¥89,681 million. As a result, gross profit was ¥60,158 million, the same as in the previous fiscal year. SG&A expenses declined 0.9% year on year to ¥54,589 million due to decreases in sales promotion expenses and personnel expenses. Accordingly, Takara Shuzo recorded operating income up 9.8% year on year to ¥5,569 million.

(Takara Shuzo International Group)

The Takara Shuzo International Group expanded the Overseas Alcoholic Beverages Business, which entails exports from Japan and the manufacture and sale of alcoholic beverages in overseas locations, and the Japanese Food Wholesale Business in overseas markets, through which it sells Japanese food ingredients to Japanese food restaurants and retailers outside Japan. With the global market for Japanese foods growing larger in a trend that is expected to continue, the Takara Shuzo International Group worked on business activities with the aim of establishing itself as a leading company in the global Japanese alcoholic beverages and food markets by letting the world know about the great taste of traditional Japanese alcoholic beverages such as sake and shochu in addition to Japanese food.

Sales in the Japanese Food Wholesale Business in overseas markets increased with the contribution of sales from Mutual Trading Co., Inc. (U.S.), which became a consolidated subsidiary during the previous fiscal year, and other factors. Sales of whiskey and other products also increased in the Overseas Alcoholic Beverages Business. As a result, net sales for the Takara Shuzo International Group rose 88.4% year on year to ¥70,717 million.

Cost of sales increased 94.4% year on year to ¥49,843 million. As a result, gross profit rose by 75.4% year on year to ¥20,874 million. SG&A expenses were up 89.1% year on year to ¥16,480 million mainly due to increases in personnel expenses. Accordingly, the Takara Shuzo International Group recorded operating income up 38.0% year on year to ¥4,393 million.

(Takara Bio Group)

The Takara Bio Group promoted efforts to implement the strategies of its three business segments: the Bioindustry business, the Gene Therapy business, and the AgriBio business and strengthen the business base to support these efforts with the aim of enhancing its standing as a global enterprise and regenerative medical products company and to achieve prodigious growth.

Bioindustry business

As the Takara Bio Group's core business, the Bioindustry business mainly provides products and services that support research and development activities in biotechnology-related fields as such activities become increasingly widespread ranging from basic research to the medical field.

In the Bioindustry business, although sales of scientific instruments declined, sales of research reagents and contract research services increased in the fiscal year under review ended March 31, 2018.

As a result of the above, net sales in the Bioindustry business increased 11.3% year on year to ¥29,568 million.

Gene Therapy business

In the Gene Therapy business, the Takara Bio Group promoted the development of gene therapy for cancer and other diseases utilizing the oncolytic virus HF10; the RetroNectin® Method, a proprietary and highly-efficient gene transduction

technology; the RetroNectin® expansion-culture system, a highly efficient lymphocyte propagation technology; and a genetically engineered T-cell therapy utilizing siTCR™ technology among others.

In the fiscal year under review, ended March 31, 2018, ¥500 million in revenue was received for co-development and exclusive sales agreements related to the oncolytic virus HF10.

As a result of the above, net sales in the Gene Therapy business were flat year on year at ¥500 million.

AgriBio business

The AgrioBio business utilizes the Takara Bio Group's leading-edge biotechnology to identify the scientific basis of foodstuffs. Based on this evidence, it develops, manufactures and sells functional food ingredients. The AgriBio business focuses on rolling out gagome kombu (kelp) "Fucoidan" related products, agar-derived agaro-oligosaccharide related products, ashitaba (angelica herb) "Chalcone" related products, the herb (Peucedanum japonicum) "Isosamidin" related products, yam (Dioscorea esculenta) "Yamsgenin™" related products, and mushroom-related products.

In the fiscal year under review, ended March 31, 2018, although sales of mushroom-related products increased, sales of health foods declined.

As a result of the above, net sales in the AgriBio business decreased 2.5% year on year to ¥2,243 million.

As a result, the Takara Bio Group's overall net sales increased 10.0% year on year to ¥32,312 million because sales in the contract research services business significantly exceeded the previous year in addition to the contribution of sales from a newly consolidated subsidiary. Cost of sales increased 9.9% year on year to ¥13,657 million with the increase in net sales and other factors. As a result, gross profit increased 10.0% year on year to ¥18,655 million. SG&A expenses were up 9.8% year on year to ¥15,099 million due to an increase in personnel expenses and amortization of goodwill from the newly consolidated subsidiary. Accordingly, the Takara Bio Group recorded operating income up 11.0% year on year to ¥3,555 million.

(Other)

The Other segment includes the Company's real estate leasing business and the distribution business of Group companies in Japan. Net sales of the Other segment declined 6.7% year on year to ¥36,412 million as TAKARA CHOU UN Co., Ltd. was excluded from the scope of consolidation during the fiscal year under review, ended March 31, 2018, accompanying the sale of shares in that company. Cost of sales declined by 7.7% year on year to ¥30,634 million. Consequently, gross profit decreased by 0.9% year on year to ¥5,777 million. SG&A expenses fell by 5.5% year on year to ¥3,458 million. As a result, operating income increased by 7.0% year on year to ¥2,318 million.

Breakdown of sales results by product category

Segment	Previous Fiscal Year (From April 1, 2016 to March 31, 2017)	Fiscal Year under Review (From April 1, 2017 to March 31, 2018)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo			
Shochu	57,404	55,034	95.9
Sake	22,387	22,222	99.3
Light-alcohol refreshers	31,097	34,267	110.2
Other alcoholic beverages	6,901	6,639	96.2
Alcoholic beverages total	117,791	118,163	100.3
Hon Mirin	14,506	14,063	96.9
Other seasonings	9,383	9,760	104.0
Seasonings total	23,889	23,823	99.7
Raw alcohol, etc.	7,771	7,852	101.0
Total	149,452	149,839	100.3
Takara Shuzo International Group			
Overseas Alcoholic Beverages Business	9,402	10,483	111.5
Japanese Food Wholesales Business in overseas markets	28,963	62,079	214.3
Other	-	49	-
Elimination of intraGroup transaction on consolidation	(825)	(1,895)	-
Total	37,540	70,717	188.4
Takara Bio Group	29,375	32,312	110.0
Reported segment total	216,369	252,870	116.9
Other	39,017	36,412	93.3
Segment total	255,386	289,282	113.3
Sales not allocated to business segments and intersegment transactions	(21,193)	(21,140)	-
Total	**234,193**	**268,142**	**114.5**

Notes: Amounts include alcohol tax but do not include consumption tax.

(2) Overview of Financial Position for the Fiscal Year under Review

(Assets)

At the end of the fiscal year under review, current assets totaled ¥173,352 million, a decrease of ¥559 million compared with that at the end of the previous fiscal year. This was primarily due to a decrease in cash and deposits of ¥10,318 million, an increase in securities of ¥6,483 million and in increase in merchandise and finished goods of ¥2,679 million. Noncurrent assets were ¥113,707 million, an increase of ¥13,250 million compared with that at the end of the previous fiscal year. This was primarily because of an increase in goodwill of ¥7,139 million, an increase in other intangible assets of ¥4,873 million, an increase in investment securities of ¥3,024 million, and a decrease in property, plant and equipment of ¥1,688 million.

As a result, total assets were ¥287,059 million, an increase of ¥12,691 million compared with that at the end of the previous fiscal year.

(Liabilities)

At the end of the fiscal year under review, current liabilities totaled ¥52,712 million, a decrease of ¥12,794 million compared with that at the end of the previous fiscal year. This was mainly due to decreases in short-term loans payable of ¥3,985 million and current portion of bonds of ¥10,000 million. Noncurrent liabilities were ¥58,130 million, an increase of ¥15,188 million compared with that at the end of the previous fiscal year. This was primarily due to an increase in bonds of ¥15,000 million.

As a result, total liabilities were ¥110,842 million, an increase of ¥2,394 million compared with that at the end of the previous fiscal year

(Net Assets)

At the end of the fiscal year under review, total net assets were ¥176,217 million, an increase of ¥10,296 million compared with that at the end of the previous fiscal year. The main factor was ¥11,029 million in net income attributable to owners of the parent.

As a result, equity ratio totaled 50.6%, compared with 49.2% at the end of the previous fiscal year.

(3) Overview of Cash Flows for the Fiscal Year under Review

Net cash provided by operating activities increased ¥3,439 million year on year to ¥16,265 million primarily due to profit before income taxes of ¥18,903 million, depreciation and amortization of ¥6,430 million, gain on sales of shares of subsidiaries and associates of ¥3,312 million, an increase in inventories of ¥2,520 million, an increase in accrued alcohol tax of ¥1,685 million and income taxes paid of ¥6,017 million.

Net cash used in investment activities resulted in expenditure of ¥19,916 million compared with revenue of ¥16,200 million in the previous fiscal year primarily due to payments into time deposits of ¥13,993 million, proceeds from the withdrawal of time deposits of ¥12,160 million, the purchase of securities of ¥12,502 million, proceeds from the sale and redemption of securities of ¥8,736 million, purchase of property, plant and equipment and intangible assets of ¥6,601 million, purchase of shares of subsidiaries resulting in change in scope of consolidation of ¥12,396 million, and proceeds from sales of shares of subsidiaries resulting in change in scope of consolidation of ¥4,150 million.

Net cash used in financing activities increased by ¥2,741 million year on year to ¥5,570 million primarily due to a decrease in short-term loans payable of ¥3,356 million, proceeds from issuance of bonds of ¥14,887 million, and expenditures of ¥10,547 million for redemption of bonds, ¥2,001 million for acquisition of treasury stock and ¥2,614 million for cash dividends paid.

As a result, cash and cash equivalents at fiscal year-end, including the effect of exchange rate change on cash and cash equivalents, stood at ¥49,341 million, down ¥9,423 million from the previous fiscal year-end.

(4)Future Outlook

The Group initiated the Takara Group Medium-Term Management Plan FY2020 (the “Medium-Term Management Plan”) in the fiscal year ended March 31, 2018, as the last step towards achieving its long-term Takara Group Vision 2020. By further increasing the overseas sales ratio together with having a full product line-up and many products with a competitive edge in Japan and overseas, the Group engaged in business activities with the aim to build up a great number of fields in which it can beat competitors and establish a balanced business foundation able to grow revenues significantly no matter what environmental changes occur.

Under the Medium-Term Management Plan, the tangible goals are as follows. Operating income in the fiscal year ended March 31, 2018, the first year of the Medium-Term Management Plan, reached the level to be achieved in the figures of the plan for the fiscal year ending March 31, 2020, the final year. Thus, all of the tangible goals have been upwardly revised from the figures in the plan.

Tangible goals (fiscal year ending March 31, 2020)
Takara Group consolidated basis
- Net sales: At least ¥295.0 billion (initial plan: at least ¥290.0 billion)
- Operating income: At least ¥18.7 billion (initial plan: at least ¥15.5 billion)
- Overseas sales ratio: At least 35% (initial plan: at least 33%)

The tangible goals for each business segment are as follows.
Takara Shuzo
Current results are progressing steadily compared with the initial plan, and the plan figures for both net sales and operating income are unchanged.
- Net sales: At least ¥160.0 billion (initial plan: at least ¥160.0 billion)
- Operating income: At least ¥6.2 billion (initial plan: at least ¥6.2 billion)

Takara Shuzo International Group
Due to the positive business environment in Europe and the U.S., current results are progressing beyond the initial plan, so the plan figures for both net sales and operating income are upwardly revised.
- Net sales: At least ¥83.0 billion (initial plan: at least ¥75.0 billion)
- Operating income: At least ¥5.2 billion (initial plan: at least ¥4.3 billion)

Takara Bio Group

Taking account of the current steady results and the impact associated with the conclusion of co-development and exclusive sales agreements related to gene therapy and other changes, the plan figure for operating income is upwardly revised.

- Net sales: At least ¥38.5 billion (initial plan: at least ¥38.5 billion)
- Operating income: At least ¥6.0 billion (initial plan: at least ¥4.0 billion)

As regards the outlook for results for the following fiscal year, the fiscal year ending March 31, 2019, which is the second year of the Medium-Term Management Plan, the Group is forecasting a net sales increase of 5.2% year on year to ¥282,000 million, an operating income increase of 10.8% year on year to ¥17,300 million and a decrease in net income attributable to owners of the parent of 13.0% year on year to ¥9,600 million.

The Medium-Term Management Plan business strategies and the outlook for results in the coming fiscal year for each segment are as follows.

The aim for Takara Shuzo is to establish a firm position as the number one maker of Japanese alcoholic beverages in the domestic alcoholic beverage and seasonings markets by expanding sales and profit ratios in every category with a focus on sake. As concerns results for the coming fiscal year, Takara Shuzo is forecasting an increase in net sales of 2.8% year on year to ¥154,000 million due to an increase in sales of alcohol and light alcohol refreshers and an increase in operating income of 9.5% year on year to ¥6,100 million.

The aim for the Takara Shuzo International Group is to dramatically expand its scope of business by enlarging its overseas Japanese food wholesaler network, together with developing its business foundation and strengthening its position with the goal of becoming a leading company in the global Japanese alcoholic beverage and foods market. As concerns results for the coming fiscal year, the Takara Shuzo International Group is forecasting an increase in net sales of 10.3% year on year to ¥78,000 million due to the expansion of the Japanese Food Wholesale Business in overseas markets and an increase in operating income of 11.5% year on year to ¥4,900 million.

The aim for the Takara Bio Group is to promote the strategies of the Bioindustry, Gene Therapy, and AgriBio businesses and strengthen the management bases which support these strategies to enhance its presence as a global company and manufacturer of regenerative medicine products. As concerns results for the coming fiscal year, the Takara Bio Group is forecasting an increase in net sales of 13.9% year on year to ¥36,800 million and an increase in operating income of 40.6% year on year to ¥5,000 million.

The above results forecast was created based on information obtainable at the time of the publication of this document and actual results may differ due to a variety of factors going forward.

2. Basic concept on selection of accounting standards

Disclosure is omitted due to the lack of any significant change from the details disclosed in the Consolidated Financial Statements for the Fiscal Year Ended March 31, 2014 (disclosed on May 8, 2014).

4. Consolidated Quarterly Financial Statements

(1) Consolidated Quarterly Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2017	As of Mar. 31, 2018
Assets		
Current assets		
Cash and deposits	58,073	47,754
Notes and accounts receivable-trade	51,392	51,199
Electronically recorded monetary claims-operating	6,558	6,690
Securities	13,237	19,721
Merchandise and finished goods	35,300	37,979
Work in process	1,244	997
Raw materials and supplies	3,306	3,932
Deferred tax assets	2,112	2,284
Other	2,922	3,122
Allowance for doubtful accounts	(236)	(329)
Total current assets	173,912	173,352
Noncurrent assets		
Property, plant and equipment		
Buildings and structures	53,980	53,842
Accumulated depreciation	(33,028)	(33,856)
Buildings and structures, net	20,952	19,986
Machinery, equipment and vehicles	82,563	83,143
Accumulated depreciation	(70,247)	(70,585)
Machinery, equipment and vehicles, net	12,315	12,557
Land	20,089	18,821
Lease assets	2,056	1,050
Accumulated depreciation	(959)	(494)
Lease assets, net	1,096	555
Construction in progress	262	1,064
Other	14,609	15,462
Accumulated depreciation	(10,152)	(10,962)
Other, net	4,457	4,499
Total property, plant and equipment	59,174	57,485
Intangible assets		
Goodwill	6,626	13,765
Other	3,630	8,504
Total intangible assets	10,256	22,269
Investments and other assets		
Investment securities	25,583	28,607
Net defined benefit asset	896	928
Deferred tax assets	1,496	1,783
Other	3,140	2,709
Allowance for doubtful accounts	(90)	(77)
Total investments and other assets	31,025	33,951
Total noncurrent assets	100,456	113,707
Total assets	274,368	287,059

(Millions of Yen)

	As of Mar. 31, 2017	As of Mar. 31, 2018
Liabilities		
Current liabilities		
Notes and accounts payable-trade	16,804	16,544
Short-term loans payable	9,206	5,221
Current portion of bonds	10,000	—
Accrued alcohol tax	7,593	9,278
Accrued expenses	5,562	5,639
Income taxes payable	2,468	3,126
Provision for bonuses	2,449	2,286
Other provision	1,899	1,853
Other	9,521	8,760
Total current liabilities	65,506	52,712
Noncurrent liabilities		
Bonds payable	10,000	25,000
Long-term loans payable	10,996	10,620
Deferred tax liabilities	5,564	6,293
Net defined benefit liability	8,961	8,759
Long-term deposits received	5,342	5,312
Other	2,075	2,144
Total noncurrent liabilities	42,941	58,130
Total liabilities	108,447	110,842
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	1,650	2,219
Retained earnings	119,729	117,571
Treasury stock	(9,939)	(1,367)
Total shareholders' equity	124,667	131,649
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	9,583	11,520
Deferred gains or losses on hedges	0	(120)
Foreign currency translation adjustment	1,426	2,645
Remeasurements of defined benefit plans	(634)	(583)
Total accumulated other comprehensive income	10,375	13,461
Noncontrolling interests	30,877	31,106
Total net assets	165,920	176,217
Total liabilities and net assets	274,368	287,059

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

(Consolidated Statements of Income)

(Millions of Yen)

	FY2017 (Apr. 1, 2016 – Mar. 31, 2017)	FY2018 (Apr. 1, 2017 – Mar. 31, 2018)
Net sales	234,193	268,142
Cost of sales	140,182	163,529
Gross profit	94,010	104,612
Selling, general and administrative expenses	80,458	88,999
Operating income	13,551	15,612
Non-operating income		
Interest income	193	191
Dividends income	465	509
Subsidy income	288	239
Other	589	467
Total non-operating income	1,537	1,408
Non-operating expenses		
Interest expenses	481	568
Bond issuance cost	—	112
Other	262	255
Total non-operating expenses	744	936
Ordinary income	14,344	16,084
Extraordinary income		
Gain on sales of subsidiaries and affiliates' stocks	—	3,312
Gain on step acquisitions	878	—
Other	248	186
Total extraordinary income	1,126	3,499
Extraordinary loss		
Loss on sales and retirement of noncurrent assets	264	222
Impairment loss	667	446
Other	18	11
Total extraordinary losses	950	679
Income before income taxes and minority interests	14,520	18,903
Income taxes-current	5,208	6,859
Income taxes-deferred	74	(484)
Total income taxes	5,283	6,374
Net income	9,236	12,528
Net income attributable to the noncontrolling interest	755	1,499
Net income attributable to owners of the parent	8,480	11,029

(Consolidated Quarterly Statements of Comprehensive Income)

(Millions of Yen)

	FY2017 (Apr. 1, 2016 – Mar. 31, 2017)	FY2018 (Apr. 1, 2017 – Mar. 31, 2018)
Net income	9,236	12,528
Other comprehensive income		
Valuation difference on available-for-sale securities	2,760	1,936
Deferred gains or losses on hedges	446	(115)
Foreign currency translation adjustment	(4,310)	1,262
Remeasurements of defined benefit plans	(348)	93
Total other comprehensive income	(1,451)	3,177
Comprehensive income	7,784	15,706
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	7,300	14,114
Comprehensive income attributable to noncontrolling interest	483	1,591

(3) Consolidated Statements of Change in Net Assets

FY2017 (Apr. 1, 2016– Mar. 31, 2017)

(Millions of Yen)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity
Balance at the beginning of current period	13,226	1,879	113,663	(9,938)	118,830
Changes of items during the period					
Dividends from surplus			(2,414)		(2,414)
Net income			8,480		8,480
Purchase of treasury stock				(0)	(0)
Disposal of treasury stock		0		0	0
Retirement of treasury shares					-
Purchase of shares of consolidated subsidiaries		(229)			(229)
Transfer to capital surplus from retained earnings					-
Net changes of items other than shareholders' equity					
Total changes of items during the period	-	(229)	6,066	(0)	5,836
Balance at the end of current period	13,226	1,650	119,729	(9,939)	124,667

	Accumulated other comprehensive income					Minority interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at the beginning of current period	6,822	(445)	5,548	(370)	11,555	25,762	156,148
Changes of items during the period							
Dividends from surplus							(2,414)
Net income							8,480
Purchase of treasury stock							(0)
Disposal of treasury stock							0
Retirement of treasury shares							-
Purchase of shares of consolidated subsidiaries							(229)
Transfer to capital surplus from retained earnings							-
Net changes of items other than shareholders' equity	2,760	445	(4,122)	(264)	(1,179)	5,115	3,935
Total changes of items during the period	2,760	445	(4,122)	(264)	(1,179)	5,115	9,771
Balance at the end of current period	9,583	0	1,426	(634)	10,375	30,877	165,920

FY2018 (Apr. 1, 2017 – Mar. 31, 2018)

(Millions of Yen)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity
Balance at the beginning of current period	13,226	1,650	119,729	(9,939)	124,667
Changes of items during the period					
Dividends from surplus			(2,615)		(2,615)
Net income			11,029		11,029
Purchase of treasury stock				(2,001)	(2,001)
Disposal of treasury stock		0		0	0
Retirement of treasury shares		(10,572)		10,572	
Purchase of shares of consolidated subsidiaries		570			570
Transfer to capital surplus from retained earnings		10,572	(10,572)		-
Net changes of items other than shareholders' equity					
Total changes of items during the period	-	569	(2,158)	8,571	6,982
Balance at the end of current period	13,226	2,219	117,571	(1,367)	131,649

	Accumulated other comprehensive income					Minority interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at the beginning of current period	9,583	0	1,426	(634)	10,375	30,877	165,920
Changes of items during the period							
Dividends from surplus							(2,615)
Net income							11,029
Purchase of treasury stock							(2,001)
Disposal of treasury stock							0
Retirement of treasury shares							-
Purchase of shares of consolidated subsidiaries							570
Transfer to capital surplus from retained earnings							-
Net changes of items other than shareholders' equity	1,936	(121)	1,218	51	3,085	228	3,314
Total changes of items during the period	1,936	(121)	1,218	51	3,085	228	10,296
Balance at the end of current period	11,520	(120)	2,645	(583)	13,461	31,106	176,217

(4) Consolidated Statements of Cash Flows

(Millions of Yen)

	FY2017 (Apr. 1, 2016 – Mar. 31, 2017)	FY2018 (Apr. 1, 2017 – Mar. 31, 2018)
Net cash provided by (used in) operating activities		
Income before income taxes and minority interests	14,520	18,903
Depreciation and amortization	5,171	6,430
Impairment loss	667	446
Amortization of goodwill	586	843
Interest and dividends income	(659)	(700)
Interest expenses	481	568
Gain (loss) on sales of subsidiaries and affiliates' stocks	—	(3,312)
Gain (loss) on step acquisitions	(878)	—
Decrease (increase) in notes and accounts receivable-trade	(1,334)	(240)
Decrease (increase) in inventories	(1,377)	(2,520)
Increase (decrease) in notes and accounts payable-trade	208	(10)
Increase (decrease) in liquor taxes payable	(261)	1,685
Increase (decrease) in accrued consumption taxes	478	176
Other, net	220	(146)
Subtotal	17,823	22,123
Interest and dividends income received	697	719
Interest expenses paid	(475)	(560)
Income taxes paid	(5,218)	(6,017)
Net cash provided by (used in) operating activities	12,826	16,265
Net cash provided by (used in) investing activities		
Payments into time deposits	(7,510)	(13,993)
Proceeds from withdrawal of time deposits	15,959	12,160
Purchase of securities	(10,059)	(12,502)
Proceeds from sales and redemption of securities	22,028	8,736
Purchase of property, plant and equipment and intangible assets	(5,376)	(6,601)
Purchase of securities	(11)	(280)
Purchase of investments in subsidiaries resulting in change in scope of consolidation	(1,327)	(12,396)
Proceeds from acquisition in subsidiaries resulting in change in scope of consolidation	2,070	—
Proceeds from sales of shares of subsidiaries resulting in change in scope of consolidation	—	4,150
Other, net	426	811
Net cash provided by (used in) investing activities	16,200	(19,916)
Net cash provided by (used in) financing activities		
Net increase (decrease) in short-term loans payable	72	(3,356)
Repayments of long-term loans payable	(108)	(858)
Proceeds from issuance of bonds	—	14,887
Redemption of bonds	—	(10,547)
Purchase of treasury shares	(0)	(2,001)
Cash dividends paid	(2,413)	(2,614)
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation	—	(585)
Other, net	(379)	(493)
Net cash provided by (used in) financing activities	(2,828)	(5,570)
Effect of exchange rate change on cash and cash equivalents	31	(202)
Net increase (decrease) in cash and cash equivalent	26,228	(9,423)
Cash and cash equivalents at beginning of period	32,536	58,765
Cash and cash equivalents at end of period	58,765	49,341

(5) Notes to Consolidated Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Segment Information)

1. Overview of Reported Segments

Reporting segments are the segments of the Takara Group for which financial information can be obtained. The Board of Directors, top organization for decision making on Group management, examines such information to determine the allocation of management resources and evaluate the business performance on a regular basis.

The Group consists of the corporate groups centered on the operating companies Takara Shuzo Co., Ltd., Takara Shuzo International Co., Ltd. and Takara Bio Inc.; other businesses; and the Company, which manages the whole group as the holding company. All operating companies develop comprehensive business strategies, covering both domestic and overseas operations, for the goods, products and services that they offer, and work to expand their business operations.

Accordingly, the Group has defined three reported segments based on the content of goods, products and services, while taking into consideration the scope of managerial responsibility and the capacity to evaluate business performance. These three reported segments are Takara Shuzo, the Takara Shuzo International Group, and the Takara Bio Group.

Takara Shuzo primarily engages in the manufacture and sale of alcoholic beverages and seasonings in Japan. The Takara Shuzo International Group engages in the export of alcoholic beverages from Japan, the manufacture and sale of alcoholic beverages at overseas locations, and the Japanese Food Wholesale Business in overseas markets. The Takara Bio Group engages in the manufacture and sale of products such as research reagents, scientific instruments, and mushrooms, as well as contract research services and research and development of gene and cell therapies.

The meeting of the Company's Board of Directors held on February 16, 2017 resolved to spin off (incorporation type company split) the overseas business of Takara Shuzo Co., Ltd., a consolidated subsidiary of the Company, and transfer it to the newly established Takara Shuzo International Co., Ltd. on July 3, 2017. As a result of revising its reporting segments in accordance with this, the Company changed its reporting segments to "Takara Shuzo," "Takara Shuzo International Group," and "Takara Bio Group" starting from the fiscal year under review, ended March 31, 2018.

The segment information for the previous fiscal year, ended March 31, 2017 discloses information prepared based on the post-change segments.

2. Calculation method for net sales, income or loss, assets, liabilities, and other items of each reported segment

The accounting treatment of reported business segments is generally the same as that explained in "Basis of Presentation of Consolidated Financial Statements."

The figures for the income of reported segments are based on operating income. Intersegment income is based on the prevailing market price.

3. Net sales, Income (Loss), Assets and Other items by Reported Segment

Previous Fiscal Year (From April 1, 2016, to March 31, 2017)

Information for the fiscal year ended March 31, 2017 stated based on post-change classifications.

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated financial statements (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	149,408	37,278	28,529	215,216	18,976	234,193	0	234,193
Intersegment	44	262	845	1,152	20,041	21,193	(21,193)	-
Total	149,452	37,540	29,375	216,369	39,017	255,386	(21,193)	234,193
Segment income	5,071	3,182	3,202	11,456	2,167	13,624	(72)	13,551
Segment assets	90,931	64,759	67,143	222,834	23,061	245,895	28,472	274,368
Other items								
Depreciation and amortization	2,196	623	1,722	4,542	437	4,979	191	5,171

Amortization of goodwill	-	424	162	586	-	586	-	586
Investment in equity-method affiliates	-	-	-	-	-	-	1,407	1,407
Increase in total fixed assets, property, plant and equipment and intangible assets	2,188	763	1,648	4,600	666	5,267	1,391	6,658

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income comprises intersegment eliminations of ¥(61) million and losses of the Company not allocated to business segments of ¥(11) million.
(3) Segment assets include assets of the Company not allocated to business segments of ¥47,963 million and other adjustment (principally eliminations) of ¥(19,490) million. Assets attributed to the Company include surplus funds and long-term investment assets.
(4) Depreciation and amortization comprises depreciation and amortization recognized by the Company.
(5) Investment in equity-method affiliates comprises investments in equity-method affiliates not allocated to business segments.
(6) Increase in total fixed assets, property, plant and equipment and intangible assets comprises increases recognized by the Company.
3. Segment income has been adjusted to the operating income of consolidated financial statements.

Fiscal Year under Review (From April 1, 2017, to March 31, 2018)

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated financial statements (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	149,426	70,456	31,617	251,500	16,633	268,133	8	268,142
Intersegment	413	261	694	1,369	19,778	21,148	(21,148)	-
Total	149,839	70,717	32,312	252,870	36,412	289,282	(21,140)	268,142
Segment income (loss)	5,569	4,393	3,555	13,518	2,318	15,836	(224)	15,612
Segment assets	95,131	68,239	68,854	232,225	19,587	251,812	35,246	287,059
Other items								
Depreciation and amortization	2,225	938	2,568	5,733	309	6,042	387	6,430
Amortization of goodwill	-	353	489	843	-	843	-	843
Investment in equity-method affiliates	-	-	-	-	-	-	1,490	1,490
Increase in total fixed assets, property, plant and equipment and intangible assets	2,696	1,677	1,539	5,913	252	6,165	249	6,414

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income comprises intersegment eliminations of ¥79 million and losses of the Company not allocated to business segments of ¥(303) million.
(3) Segment assets include assets of the Company not allocated to business segments of ¥55,784 million and other adjustment (principally eliminations) of ¥(20,537) million. Assets attributed to the Company include surplus funds and long-term investment assets.
(4) Depreciation and amortization comprises depreciation and amortization recognized by the Company.
(5) Investment in equity-method affiliates comprises investments in equity-method affiliates not allocated to business segments.
(6) Increase in total fixed assets, property, plant and equipment and intangible assets comprises increases recognized by the Company.
3. Segment income has been adjusted to the operating income of consolidated financial statements.

(Per Share Information)

	Previous Fiscal Year (From April 1, 2016, to March 31, 2017)	Fiscal Year under Review (From April 1, 2017, to March 31, 2018)
Net assets per share	¥671.11	¥726.90
Profit per share	¥42.15	¥54.97

Notes: 1. Fully diluted profit per share is not presented since there were no potential shares.

2. The basis of calculation of net assets per share is as follows.

	Previous Fiscal Year (As of March 31, 2017)	Fiscal Year under Review (As of March 31, 2018)
Total net assets (¥ million)	165,920	176,217
Amount deducted from total net assets (¥ million)	30,877	31,106
(of which minority interests) (¥ million)	(30,877)	(31,106)
Net assets at term-end related to shares of common stock (¥ million)	135,043	145,111
Shares of common stock at term-end used to calculate net assets per share (1,000 shares)	201,224	199,630

3. The basis of calculation of net income per share and fully diluted net income per share is as follows.

	Previous Fiscal Year (From April 1, 2016, to March 31, 2017)	Fiscal Year under Review (From April 1, 2017, to March 31, 2018)
Net income attributable to owners of the parent (¥ million)	8,480	11,029
Amount not belonging to common shareholders (¥ million)	-	-
Net income related to shares of common stock (¥ million)	8,480	11,029
Average number of shares outstanding during the term (1,000 shares)	201,224	200,632

(Significant Subsequent Events)

(Conclusion of Important Agreement)

Takara Bio Inc (Takara Bio), a consolidated subsidiary of the Company, entered into an agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for co-development and exclusive sales in Japan of NY-ESO-1 siTCR™ gene therapy product (TBI-1301 and TBI-1301-A) and CD19 CAR gene therapy product (TBI 1501) as of April 9, 2018.

Under the agreement, both companies will aim cooperatively for the early manufacture and sales approval of the two therapeutic products in Japan. Specifically, Takara Bio is responsible for examining manufacturing methods for the two therapeutic products and manufacturing and quality control of the investigational products, while Otsuka is responsible for clinical trials, other clinical studies, regulatory submissions for manufacturing and sales approval, and safety data collection for both the products. After acquisition of manufacturing and sales approval, Takara Bio and Otsuka are exclusively responsible for manufacturing and selling in Japan respectively. There are no limitations on the target indications in the agreement. Otsuka also holds a right of first refusal for nine Asian countries outside Japan.

Takara Bio will receive certain upfront and milestone payments from Otsuka depending on the achievement of certain stages of development based on the execution of the agreement. Takara Bio will supply Otsuka with the products for a financial consideration after the market launch of the products. As for NY-ESO-1 siTCR™ gene therapy products, Takara Bio will receive milestone payments upon the achievement of target sales in addition to the running royalties on net sales.

平成30年3月期
決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Year Ended March 31, 2018

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
   ① グループ別要約損益計算書
   Consolidated Statements of Income by Business Group (Summary)
   ② 要約貸借対照表
   Consolidated Balance Sheets (Summary)
2. 宝酒造
Takara Shuzo Co.,Ltd.
   要約損益計算書
   Statements of Income (Summary)
3. 宝酒造インターナショナルグループ
Takara Shuzo International Group
   要約損益計算書
   Statements of Income (Summary)
4. タカラバイオグループ
Takara Bio Group
   要約損益計算書
   Statements of Income (Summary)
5. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group
6. 平成30年3月期　参考資料
Reference Data for the Year Ended March 31, 2018
7. 平成31年3月期 業績予想
Financial forecast for the year ending March 31, 2019
   ① 宝ホールディングス(連結)
   Takara Holdings Inc. -Consolidated-
   ② 宝酒造
   Takara Shuzo Co.,Ltd.
   ③ 宝酒造インターナショナルグループ
   Takara Shuzo International Group
   ④ タカラバイオグループ
   Takara Bio Group
8. 平成31年3月期　参考資料
Reference Data for the year ending March 31, 2019

宝ホールディングス株式会社
TAKARA HOLDINGS INC.
IR部 Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5194
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　IR部

Takara Holdings Inc. Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5194

E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

① グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	平成29年3月期 FY2017	平成30年3月期 FY2018 / Apr. 1, 2017 - Mar. 31, 2018		対前期 Change from FY2017		対11/7予想 Change from forecast anounced Nov. 2017	
	実績 Actual (a)	11/7予想 Forecast announced Nov. 7, 2017 (b)	実績 Actual (c)	増減 Change (c-a)	比 % (c/a)	増減 Difference (c-b)	比 % (c/b)
宝酒造 Takara Shuzo Group	149,452	152,000	149,839	386	100.3%	△ 2,160	98.6%
宝酒造インターナショナルグループ Takara Shuzo International Group	37,540	70,000	70,717	33,176	188.4%	717	101.0%
タカラバイオ グループ Takara Bio Group	29,375	33,000	32,312	2,937	110.0%	△ 687	97.9%
その他 Other	39,017	36,000	36,412	△ 2,605	93.3%	412	101.1%
調整額 Adjustment	△ 21,193	△ 21,000	△ 21,140	53	―	△ 140	―
売上高 Net sales	234,193	270,000	268,142	33,948	114.5%	△ 1,857	99.3%
売上原価 Cost of sales	140,182	164,400	163,529	23,346	116.7%	△ 870	99.5%
売上総利益 Gross profit	94,010	105,600	104,612	10,602	111.3%	△ 987	99.1%
運送費、保管料 Transportation and storage	8,743	9,900	9,665	921	110.5%	△ 234	97.6%
広告宣伝費 Advertising	3,198	3,200	3,073	△ 124	96.1%	△ 126	96.1%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	34,292	34,500	33,688	△ 604	98.2%	△ 811	97.6%
研究開発費 Research and development	4,550	5,000	5,063	512	111.3%	63	101.3%
管理費、その他 Other, net	29,673	37,700	37,508	7,835	126.4%	△ 191	99.5%
販売費及び一般管理費 SG&A expenses	80,458	90,300	88,999	8,540	110.6%	△ 1,300	98.6%
宝酒造 Takara Shuzo Group	5,071	6,000	5,569	498	109.8%	△ 430	92.8%
宝酒造インターナショナルグループ Takara Shuzo International Group	3,182	4,500	4,393	1,210	138.0%	△ 106	97.6%
タカラバイオ グループ Takara Bio Group	3,202	3,500	3,555	352	111.0%	55	101.6%
その他 Other	2,167	2,200	2,318	151	107.0%	118	105.4%
調整額 Adjustment	△ 72	△ 900	△ 224	△ 151	―	675	―
営業利益(△:損失) Operating income(Δ:loss)	13,551	15,300	15,612	2,061	115.2%	312	102.0%
受取利息・配当金 Interest and Dividends income	659	600	700	41	106.3%	100	116.8%
その他営業外収益 Other, net	878	800	707	△ 170	80.6%	△ 92	88.4%
営業外収益 Non-operating income	1,537	1,400	1,408	△ 129	91.6%	8	100.6%
支払利息 Interest and discounts expenses	481	500	568	87	118.1%	68	113.8%
その他営業外費用 Other, net	262	400	367	104	139.7%	△ 32	91.9%
営業外費用 Non-operating expenses	744	900	936	191	125.7%	36	104.0%
経常利益(△:損失) Ordinary income(Δ:loss)	14,344	15,800	16,084	1,740	112.1%	284	101.8%
特別利益 Extraordinary income	1,126	3,500	3,499	2,372	310.5%	△ 0	100.0%
特別損失 Extraordinary loss	950	600	679	△ 271	71.5%	79	113.3%
税金等調整前当期純利益(△:損失) Income before income taxes(Δ:loss)	14,520	18,700	18,903	4,383	130.2%	203	101.1%
法人税、住民税及び事業税 Current income taxes	5,208	7,000	6,859	1,650	131.7%	△ 625	91.1%
法人税等調整額 Deferred income taxes	74		△ 484	△ 559	―		
当期純利益(△:損失) Net income(Δ:loss)	9,236	11,700	12,528	3,292	135.6%	828	107.1%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	755	1,300	1,499	744	198.5%	199	115.4%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	8,480	10,400	11,029	2,548	130.0%	629	106.0%
設備投資額(有形・無形) Capital expenditures	6,658	7,051	6,414	△ 244	96.3%	△ 636	91.0%
減価償却費(有形・無形) Depreciation and Amortization	5,171	6,600	6,430	1,259	124.3%	△ 169	97.4%
のれん償却額 Amortization of goodwill	586	840	843	256	143.8%	3	100.4%

営業外収益 Non-operating income	受取利息191、受取配当金509、補助金収入239 など Interest income 191, Dividends income 509, Subsidy income 239, etc.
営業外費用 Non-operating expenses	支払利息353、社債利息215、社債発行費112 など Interest expense 353, Interest on bonds 215, Bond issuance cost 112 etc.
特別利益 Extraordinary income	投資有価証券売却益160、関係会社株式売却益3,312 など Gain on sales of investment securities 160, Gain on sales of subsidiaries and affiliates' stocks 3,312 etc.
特別損失 Extraordinary loss	固定資産除売却損222、減損損失446 など Loss on sales and retirement of noncurrent assets 222, Impairment loss 446 etc.

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

資産の部 :Assets　　（百万円 :Millions of Yen）

	平成29年3月期末 As of Mar. 31, 2017	平成30年3月期末 As of Mar. 31, 2018	増減 Change	主な増減理由 Reference
(流動資産) (Total current assets)	173,912	173,352	△ 559	（億円 :One hundred millions of Yen）
現金及び預金 Cash and deposits	58,073	47,754	△ 10,318	タカラバイオUSA △132.2、宝HLD △62.0、宝酒造 +44.4 Takara Bio USA △132.2, Takara Holdings △62.0, Takara Shuzo +44.4
受取手形及び売掛金 Notes and accounts receivable-trade	57,951	57,889	△ 61	
有価証券 Marketable securities	13,237	19,721	6,483	宝HLD＋113.0、USA宝HLD△47.8 Takara Holdings +113.0, USA Takara Holding △47.8
たな卸資産 Inventories	39,851	42,909	3,058	
その他 Other current assets	5,035	5,406	371	
貸倒引当金 Allowance for doubtful accounts	△ 236	△ 329	△ 93	
(固定資産) (Total fixed assets)	100,456	113,707	13,250	
〔有形固定資産〕 [Property, plant and equipment]	59,174	57,485	△ 1,688	
建物及び構築物 Buildings and structures	20,952	19,986	△ 966	（当期の有形・無形固定資産の増減内訳） Reference of Property, plant and equipment and Intangible assets
機械装置及び運搬具 Machinery, equipment and vehicles	12,315	12,557	241	新規取得 ＋64.1 （TS＋26.9、TSI＋16.7、TB＋15.3） Newly purchases +64.1
土地 Land	20,089	18,821	△ 1,268	減価償却 △64.3 （TS△22.2、TSI△9.3、TB△25.6） Depreciation Δ64.3
その他 Other property, plant and equipment	5,816	6,120	303	その他増減 +103.4 Other, net +103.4
〔無形固定資産〕 [Intangible fixed assets]	10,256	22,269	12,013	
のれん Goodwill	6,626	13,765	7,139	タカラバイオUSA +76.1 Takara Bio USA +76.1
その他 Other intangible fixed assets	3,630	8,504	4,873	タカラバイオUSA +47.6 Takara Bio USA +47.6
〔投資その他の資産〕 [Investments and other assets]	31,025	33,951	2,926	
投資有価証券 Investment securities	25,583	28,607	3,024	
その他 Other assets	5,533	5,421	△ 111	
貸倒引当金 Allowance for doubtful accounts	△ 90	△ 77	13	
資産合計 Total assets	274,368	287,059	12,691	

(TH=Takara Holdings Inc., TS=Takara Shuzo Co.,Ltd., TSI=Takara Shuzo International Group, TB=Takara Bio Group)

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

負債及び純資産 の部 :Liabilities and net assets （百万円 :Millions of Yen）

	平成29年3月期末 As of Mar. 31, 2017	平成30年3月期末 As of Mar. 31, 2018	増減 Change	主な増減理由 Reference
(流動負債) (Total current liabilities)	65,506	52,712	△ 12,794	(億円 :One hundred millions of Yen)
支払手形及び買掛金 Notes and accounts payable-trade	16,804	16,544	△ 259	
短期借入金 Short-term loans payable	9,206	5,221	△ 3,985	ミューチャルトレーディング △39.9 Mutual Trading Co., Inc. △39.9
1年内償還の社債 Current portion of bonds	10,000	―	△ 10,000	宝HLD△100.0 Takara Holdings △100.0 第9回普通社債(2017年9月償還)、第12回普通社債(2017年4月償還) #9SB (Redemption, Sept. 2017)、#12SB (Redemption, Apr. 2017)
未払酒税 Accrued alcohol tax	7,593	9,278	1,685	宝酒造 +16.8 Takara Shuzo +16.8
未払費用 Accrued expenses	5,562	5,639	77	
販売促進引当金 Reserve for sales promotion expenses	1,899	1,853	△ 46	
その他 Other current liabilities	14,439	14,174	△ 265	
(固定負債) (Total non-current liabilities)	42,941	58,130	15,188	
社債 Bonds payable	10,000	25,000	15,000	宝HLD+150.0 Takara Holdings +150.0 第14回(2022年4月償還)、第15回(2024年4月償還)、第16回普通社債(2027年4月償還) #14SB (Redemption, Apr. 2022)、#15SB (Redemption, Apr. 2024)、#16SB (Redemption, Sept. 2027)
長期借入金 Long-term loans payable	10,996	10,620	△ 376	
退職給付に係る負債 Net defined benefit liability	8,961	8,759	△ 201	
預り金 Deposits from customers	5,342	5,312	△ 30	
その他 Other non-current liabilities	7,640	8,437	797	
負債合計 Total liabilities	108,447	110,842	2,394	
資本金 Capital stock	13,226	13,226	―	
資本剰余金 Capital surplus	1,650	2,219	569	
利益剰余金 Retained earnings	119,729	117,571	△ 2,158	
自己株式 Treasury stock	△ 9,939	△ 1,367	8,571	消却 105.7、 取得△20.0 Cancellation +105.7, Acquisitions △20.0
(株主資本) (Total owner's equity)	124,667	131,649	6,982	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	9,583	11,520	1,936	
繰延ヘッジ損益 Deffered gains or losses on hedges	0	△ 120	△ 121	
為替換算調整勘定 Translation adjustments	1,426	2,645	1,218	TSI +12.0、TB +11 USD=113.05JPY, EUR=134.95JPY, GBP=152.02JPY (Dec. 2017) USD=116.53JPY, EUR=122.73JPY, GBP=143.06JPY (Dec. 2016)
退職給付に係る調整累計額 Remeasurements of defined benefit plans	△ 634	△ 583	51	
(その他の包括利益累計額) (Total valuation and translation adjustments)	10,375	13,461	3,085	
(非支配株主持分) (Noncontrolling interests)	30,877	31,106	228	
純資産合計 Total net assets	165,920	176,217	10,296	
負債純資産合計 Total liabilities and net assets	274,368	287,059	12,691	

(TH=Takara Holdings Inc., TS=Takara Shuzo Co.,Ltd., TSI=Takara Shuzo International Group, TB=Takara Bio Group)

2. 宝酒造 :Takara Shuzo Co., Ltd.

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成29年3月期 FY2017	平成30年3月期 FY2018 / Apr. 1, 2017 - Mar. 31, 2018		対前期 Change from FY2017		対11/7予想 Change from forecast anounced Nov. 2017	
	実績 Actual (a)	11/7予想 Forecast announced Nov. 7, 2017 (b)	実績 Actual (c)	増減 Change (c-a)	比 % (c/a)	増減 Difference (c-b)	比 % (c/b)
焼酎 Shochu	57,404	55,300	55,034	△ 2,369	95.9%	△ 265	99.5%
清酒 Sake	22,387	23,000	22,222	△ 165	99.3%	△ 777	96.6%
ソフトアルコール飲料 Light-alcohol refreshers	31,097	35,300	34,267	3,170	110.2%	△ 1,032	97.1%
その他酒類 Other liquors	6,901	6,600	6,639	△ 262	96.2%	39	100.6%
本みりん Hon Mirin	14,506	14,300	14,063	△ 443	96.9%	△ 236	98.3%
その他調味料 Other seasonings	9,383	9,600	9,760	376	104.0%	160	101.7%
原料用アルコール等 Raw alcohol	7,771	7,900	7,852	81	101.0%	△ 47	99.4%
売上高 Net sales	149,452	152,000	149,839	386	100.3%	△ 2,160	98.6%
売上原価 Cost of sales	89,278	90,500	89,681	402	100.5%	△ 818	99.1%
売上総利益 Gross profit	60,174	61,500	60,158	△ 16	100.0%	△ 1,341	97.8%
運送費、保管料 Transportation and storage	7,106	7,400	7,251	144	102.0%	△ 148	98.0%
広告宣伝費 Advertising	2,637	2,700	2,601	△ 35	98.6%	△ 98	96.3%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	32,923	33,100	32,342	△ 580	98.2%	△ 757	97.7%
研究開発費 Research and development	345	400	370	24	107.2%	△ 29	92.6%
管理費、その他 Other, net	12,090	11,900	12,023	△ 67	99.4%	123	101.0%
販売費及び一般管理費 SG&A expenses	55,103	55,500	54,589	△ 514	99.1%	△ 910	98.4%
営業利益（△：損失） Operating income(Δ:loss)	5,071	6,000	5,569	498	109.8%	△ 430	92.8%
営業外収益 Non-operating income	1,029	1,400	1,369	339	133.0%	△ 30	97.8%
営業外費用 Non-operating expenses	260	300	256	△ 4	98.4%	△ 43	85.5%
経常利益（△：損失） Ordinary income(Δ:loss)	5,839	7,100	6,681	842	114.4%	△ 418	94.1%
特別利益 Extraordinary gain	25	4,700	4,711	4,686	18436.2%	11	100.3%
特別損失 Extraordinary loss	114	100	150	36	132.1%	50	150.8%
税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss)	5,751	11,700	11,243	5,491	195.5%	△ 456	96.1%
法人税、住民税及び事業税 Current income taxes	1,669	3,300	2,887	1,217	172.9%	△ 389	88.2%
法人税等調整額 Deferred income taxes	—		22	22	—		
当期純利益（△：損失） Net income(Δ:loss)	4,081	8,400	8,332	4,251	204.2%	△ 67	99.2%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	—	—	—	—	—	—	—
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	4,081	8,400	8,332	4,251	204.2%	△ 67	99.2%
設備投資額（有形・無形） Capital expenditures	2,188		2,696	508	123.2%		
減価償却費（有形・無形） Depreciation and Amortization	2,196	2,300	2,225	28	101.3%	△ 74	96.8%

（注）平成29年3月期の実績において、「焼酎」「ソフトアルコール飲料」「その他酒類」の売上高の一部を前回発表時から組み替えております。

3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成29年3月期 FY2017	平成30年3月期 FY2018 / Apr. 1, 2017 - Mar. 31, 2018		対前期 Change from FY2017		対11/7予想 Change from forecast anounced Nov. 2017	
	実績 Actual (a)	11/7予想 Forecast announced Nov. 7, 2017 (b)	実績 Actual (c)	増減 Change (c-a)	比 % (c/a)	増減 Difference (c-b)	比 % (c/b)
海外酒類事業 Overseas Alcoholic beverages business	9,402	10,200	10,483	1,081	111.5%	283	102.8%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	28,963	61,800	62,079	33,116	214.3%	279	100.5%
その他 Other	—	50	49	49	—	△ 0	99.2%
連結消去 Elimination	△ 825	△ 2,050	△ 1,895	△ 1,070	—	154	—
売上高 Net sales	37,540	70,000	70,717	33,176	188.4%	717	101.0%
売上原価 Cost of sales	25,641	49,100	49,843	24,201	194.4%	743	101.5%
売上総利益 Gross profit	11,899	20,900	20,874	8,975	175.4%	△ 25	99.9%
運送費、保管料 Transportation and storage	1,191	2,100	1,921	729	161.2%	△ 178	91.5%
広告宣伝費 Advertising	93	100	89	△ 3	96.0%	△ 10	89.7%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	542	700	640	97	118.0%	△ 59	91.5%
研究開発費 Research and development	—	—	—	—	—	—	—
管理費、その他 Other, net	6,887	13,500	13,829	6,941	200.8%	329	102.4%
販売費及び一般管理費 SG&A expenses	8,716	16,400	16,480	7,764	189.1%	80	100.5%
海外酒類事業 Overseas Alcoholic beverages business	1,738	1,800	1,972	234	113.5%	172	109.6%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	2,584	3,900	3,735	1,150	144.5%	△ 164	95.8%
その他 Other	△ 611	△ 800	△ 828	△ 216	—	△ 28	—
連結消去 Elimination	△ 528	△ 400	△ 485	42	—	△ 85	—
営業利益（△：損失） Operating income(Δ:loss)	3,182	4,500	4,393	1,210	138.0%	△ 106	97.6%
営業外収益 Non-operating income	340	300	204	△ 135	60.2%	△ 95	68.3%
営業外費用 Non-operating expenses	142	300	268	125	188.3%	△ 31	89.3%
経常利益（△：損失） Ordinary income(Δ:loss)	3,381	4,500	4,330	949	128.1%	△ 169	96.2%
特別利益 Extraordinary gain	886	20	4	△ 881	0.5%	△ 15	22.3%
特別損失 Extraordinary loss	27	20	18	△ 8	67.8%	△ 1	92.7%
税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss)	4,240	4,500	4,316	76	101.8%	△ 183	95.9%
法人税、住民税及び事業税 Current income taxes	1,381	1,800	1,913	532	138.5%	△ 296	83.5%
法人税等調整額 Deferred income taxes	—		△ 409	△ 409	—		
当期純利益（△：損失） Net income(Δ:loss)	2,858	2,700	2,812	△ 46	98.4%	112	104.2%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	199	600	581	381	291.0%	△ 18	96.9%
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	2,658	2,100	2,230	△ 428	83.9%	130	106.2%
設備投資額（有形・無形） Capital expenditures	763		1,677	913	219.6%		
減価償却費（有形・無形） Depreciation and Amortization	623	910	938	315	150.6%	28	103.2%
のれん償却額 Amortization of goodwill	424	360	353	△ 70	83.4%	△ 6	98.2%

4. タカラバイオグループ :Takara Bio Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成29年3月期 FY2017	平成30年3月期 FY2018 / Apr. 1, 2017 - Mar. 31, 2018		対前期 Change from FY2017		対11/7予想 Change from forecast anounced Nov. 2017	
	実績 Actual (a)	11/7予想 Forecast announced Nov. 7, 2017 (b)	実績 Actual (c)	増減 Change (c-a)	比 % (c/a)	増減 Difference (c-b)	比 % (c/b)
研究用試薬 Research reagents	19,436	22,331	22,207	2,770	114.3%	△ 123	99.4%
理化学機器 Scientific instruments	2,911	2,945	2,635	△ 275	90.5%	△ 309	89.5%
受託・その他 Contracted service and other	4,225	4,940	4,725	500	111.8%	△ 214	95.7%
バイオ産業支援　計 Bioindustry	26,573	30,217	29,568	2,995	111.3%	△ 648	97.9%
遺伝子医療 Gene Therapy	500	500	500	―	100.0%	―	100.0%
医食品バイオ AgriBio	2,301	2,282	2,243	△ 58	97.5%	△ 39	98.3%
売上高 Net sales	29,375	33,000	32,312	2,937	110.0%	△ 687	97.9%
売上原価 Cost of sales	12,422	14,318	13,657	1,234	109.9%	△ 661	95.4%
売上総利益 Gross profit	16,952	18,681	18,655	1,702	110.0%	△ 25	99.9%
運送費、保管料 Transportation and storage	594	653	643	48	108.1%	△ 10	98.4%
広告宣伝費 Advertising	89	84	83	△ 5	93.5%	△ 1	98.6%
販売促進費 Sales promotion	854	771	729	△ 124	85.4%	△ 42	94.5%
研究開発費 Research and development	4,101	4,654	4,653	552	113.5%	△ 0	100.0%
管理費、その他 Other, net	8,110	9,016	8,990	879	110.8%	△ 26	99.7%
販売費及び一般管理費 SG&A expenses	13,749	15,180	15,099	1,349	109.8%	△ 81	99.5%
バイオ産業支援 Bioindustry	6,218	6,670	6,683	465	107.5%	13	100.2%
遺伝子医療 Gene Therapy	△ 1,380	△ 1,394	△ 1,322	57	―	71	―
医食品バイオ AgriBio	104	151	107	2	102.7%	△ 44	70.6%
共通 Eliminations/Corporate	△ 1,739	△ 1,927	△ 1,912	△ 172	―	15	―
営業利益（△：損失） Operating income(Δ:loss)	3,202	3,500	3,555	352	111.0%	55	101.6%
営業外収益 Non-operating income	445	403	402	△ 42	90.4%	△ 1	99.7%
営業外費用 Non-operating expenses	68	103	96	27	139.4%	△ 7	92.7%
経常利益（△：損失） Ordinary income(Δ:loss)	3,579	3,800	3,861	282	107.9%	61	101.6%
特別利益 Extraordinary income	2	0	0	△ 1	30.3%	0	237.1%
特別損失 Extraordinary loss	775	413	501	△ 274	64.6%	87	121.2%
税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss)	2,805	3,386	3,361	555	119.8%	△ 25	99.2%
法人税、住民税及び事業税 Current income taxes	1,492	1,376	1,155	△ 337	77.4%	△ 353	74.3%
法人税等調整額 Deferred income taxes	△ 43		△ 132	△ 88	―		
当期純利益（△：損失） Net income(Δ:loss)	1,356	2,010	2,338	981	172.4%	327	116.3%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	3	9	3	△ 0	92.3%	△ 6	31.0%
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	1,352	2,000	2,335	982	172.6%	334	116.7%
設備投資額（有形・無形） Capital expenditures	1,648		1,539	△ 109	93.4%		
減価償却費（有形・無形） Depreciation and Amortization	1,722	2,580	2,568	846	149.2%	△ 11	99.5%
のれん償却額 Amortization of goodwill	162	491	489	327	301.6%	△ 1	99.6%

5. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		平成25年3月期 FY2013	平成26年3月期 FY2014	平成27年3月期 FY2015	平成28年3月期 FY2016	平成29年3月期 FY2017	平成30年3月期 FY2018	前期対比 Change from FY2017 増減 Change	前期対比 Change from FY2017 比 YOY%
売上高	Net sales	200,989	209,568	219,490	225,364	234,193	268,142	33,948	114.5%
売上原価	Cost of sales	123,630	129,447	134,390	135,868	140,182	163,529	23,346	116.7%
（売上高原価率）	(Ratio to Net sales)	61.5%	61.8%	61.2%	60.3%	59.9%	61.0%	+1.1pt	–
売上総利益	Gross profit	77,359	80,121	85,099	89,495	94,010	104,612	10,602	111.3%
販売費及び一般管理費	SG&A expenses	68,225	70,631	74,003	77,815	80,458	88,999	8,540	110.6%
（売上高販管費率）	(Ratio to Net sales)	33.9%	33.7%	33.7%	34.5%	34.4%	33.2%	-1.2pt	–
営業利益（△：損失）	Operating income(Δ:loss)	9,133	9,490	11,096	11,680	13,551	15,612	2,061	115.2%
（売上高営業利益率）	(Ratio to Net Sales)	4.5%	4.5%	5.1%	5.2%	5.8%	5.8%	+0.0pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	32,838	32,954	32,818	33,471	34,292	33,688	Δ 604	98.2%
（売上高販促費率）	(Ratio to Net sales)	16.3%	15.7%	15.0%	14.9%	14.6%	12.6%	-2.1pt	–
研究開発費	R&D expenses	3,090	3,376	3,754	4,608	4,550	5,063	512	111.3%
（売上高研究開発費率）	(Ratio to Net sales)	1.5%	1.6%	1.7%	2.0%	1.9%	1.9%	-0.1pt	–
設備投資額（有形・無形）	Capital expenditures	5,282	8,967	9,533	6,003	6,658	6,414	Δ 244	96.3%
減価償却費（有形・無形）	Depreciation and Amortization	4,251	4,287	4,662	5,179	5,171	6,430	1,259	124.3%
のれん償却額	Amortization of goodwill	267	348	500	538	586	843	256	143.8%

宝酒造 :Takara Shuzo Co., Ltd.

（百万円 :Millions of Yen）

		平成25年3月期 FY2013	平成26年3月期 FY2014	平成27年3月期 FY2015	平成28年3月期 FY2016	平成29年3月期 FY2017	平成30年3月期 FY2018	前期対比 Change from FY2017 増減 Change	前期対比 Change from FY2017 比 YOY%
売上高	Net sales	–	–	–	–	149,452	149,839	386	100.3%
売上原価	Cost of sales	–	–	–	–	89,278	89,681	402	100.5%
（売上高原価率）	(Ratio to Net sales)	–	–	–	–	59.7%	59.9%	+0.1pt	–
売上総利益	Gross profit				–	60,174	60,158	Δ 16	100.0%
販売費及び一般管理費	SG&A expenses				–	55,103	54,589	Δ 514	99.1%
（売上高販管費率）	(Ratio to Net sales)				–	36.9%	36.4%	-0.4pt	–
営業利益（△：損失）	Operating income(Δ:loss)				–	5,071	5,569	498	109.8%
（売上高営業利益率）	(Ratio to Net sales)				–	3.4%	3.7%	+0.3pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.				–	32,923	32,342	Δ 580	98.2%
（売上高販促費率）	(Ratio to Net sales)				–	22.0%	21.6%	-0.4pt	–
設備投資額（有形・無形）	Capital expenditures	–	–	–	–	2,188	2,696	508	123.2%
減価償却費（有形・無形）	Depreciation and Amortization	–	–	–	–	2,196	2,225	28	101.3%

平成30年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

宝酒造インターナショナルグループ :Takara Shuzo International Group

（百万円 :Millions of Yen）

		平成25年3月期 FY2013	平成26年3月期 FY2014	平成27年3月期 FY2015	平成28年3月期 FY2016	平成29年3月期 FY2017	平成30年3月期 FY2018	前期対比 Change from FY2017 増減 Change	前期対比 Change from FY2017 比 YOY%
売上高	Net sales	–	–	–	–	37,540	70,717	33,176	188.4%
売上原価	Cost of sales	–	–	–	–	25,641	49,843	24,201	194.4%
（売上高原価率）	(Ratio to Net sales)	–	–	–	–	68.3%	70.5%	+2.2pt	–
売上総利益	Gross profit				–	11,899	20,874	8,975	175.4%
販売費及び一般管理費	SG&A expenses				–	8,716	16,480	7,764	189.1%
（売上高販管費率）	(Ratio to Net sales)				–	23.2%	23.3%	+0.1pt	–
営業利益（△：損失）	Operating income(Δ:loss)				–	3,182	4,393	1,210	138.0%
（売上高営業利益率）	(Ratio to Net sales)				–	8.5%	6.2%	-2.3pt	–
のれん償却後営業利益（△：損失）	Operating income after amortization of goodwill				–	2,758	4,039	1,280	146.4%
（のれん償却後営業利益率）	(Ratio to Net sales)				–	7.3%	5.7%	-1.6pt	–
設備投資額（有形・無形）	Capital expenditures	–	–	–	–	763	1,677	913	219.6%
減価償却費（有形・無形）	Depreciation and Amortization	–	–	–	–	623	938	315	150.6%
のれん償却額	Amortization of goodwill	–	–	–	–	424	353	Δ 70	83.4%

平成30年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		平成25年3月期 FY2013	平成26年3月期 FY2014	平成27年3月期 FY2015	平成28年3月期 FY2016	平成29年3月期 FY2017	平成30年3月期 FY2018	前期対比 Change from FY2017 増減 Change	前期対比 Change from FY2017 比 YOY%
売上高	Net sales	20,564	23,905	25,969	29,729	29,375	32,312	2,937	110.0%
売上原価	Cost of sales	9,540	11,331	12,142	13,405	12,422	13,657	1,234	109.9%
（売上高原価率）	(Ratio to Net sales)	46.4%	47.4%	46.8%	45.1%	42.3%	42.3%	-0.0pt	–
売上総利益	Gross profit	11,024	12,574	13,827	16,323	16,952	18,655	1,702	110.0%
販売費及び一般管理費	SG&A expenses	9,332	10,619	11,524	13,655	13,749	15,099	1,349	109.8%
（売上高販管費率）	(Ratio to Net sales)	45.4%	44.4%	44.4%	45.9%	46.8%	46.7%	-0.1pt	–
営業利益（△：損失）	Operating income(Δ:loss)	1,691	1,954	2,302	2,667	3,202	3,555	352	111.0%
（売上高営業利益率）	(Ratio to Net sales)	8.2%	8.2%	8.9%	9.0%	10.9%	11.0%	+0.1pt	–
研究開発費	R&D expenses	2,715	3,026	3,401	4,275	4,101	4,653	552	113.5%
（売上高研究開発費率）	(Ratio to Net sales)	13.2%	12.7%	13.1%	14.4%	14.0%	14.4%	+0.4pt	–
設備投資額（有形・無形）	Capital expenditures	2,397	5,538	4,762	2,090	1,648	1,539	Δ 109	93.4%
減価償却費（有形・無形）	Depreciation and Amortization	1,104	1,157	1,347	1,687	1,722	2,568	846	149.2%
のれん償却額	Amortization of goodwill	119	131	136	181	162	489	327	301.6%

（参考）宝酒造グループ :Reference Data for the Takara Shuzo Group

（百万円 :Millions of Yen）

		平成25年3月期 FY2013	平成26年3月期 FY2014	平成27年3月期 FY2015	平成28年3月期 FY2016	平成29年3月期 FY2017	平成30年3月期 FY2018	前期対比 Change from FY2017 増減 Change	前期対比 Change from FY2017 比 YOY%
売上高	Net sales	176,946	182,306	190,089	192,025	201,171	–	–	–
売上原価	Cost of sales	112,384	116,619	120,691	120,886	126,329			
売上総利益	Gross profit	64,562	65,686	69,397	71,138	74,841			
販売費及び一般管理費	SG&A expenses	58,174	59,357	61,556	62,728	65,086			
営業利益（△：損失）	Operating income(Δ:loss)	6,387	6,329	7,840	8,410	9,755			
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	31,815	31,889	31,818	32,405	33,337			
設備投資額（有形・無形）	Capital expenditures	2,529	2,954	4,594	2,919	3,269			
減価償却費（有形・無形）	Depreciation and Amortization	2,997	2,968	3,170	3,252	3,191			
のれん償却額	Amortization of goodwill	148	217	363	357	424	–	–	–

平成29年3月期までの旧セグメントです。
This is an old segment until the fiscal year ended March 2017.

6. 平成30年3月期 参考資料 :Reference Data for the Year Ended March 31, 2018

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	平成29年3月期 FY2017	平成30年3月期 FY2018 / Apr. 1, 2017 - Mar. 31, 2018			
	実績 Actual (a)	11/7予想 Forecast announced Nov. 7, 2017 (b)	実績 Actual (c)	前期差 Change(c-a)	予想差 Difference(c-b)
米ドル : US dollar	108.81	111.50	112.17	3.36	0.67
ポンド: Pound	147.64	143.00	144.50	△ 3.14	1.50
ユーロ: Euro	120.30	126.00	126.70	6.40	0.70
人民元: Yuan	16.36	16.50	16.62	0.26	0.12
100ウォン: 100 Won	9.37	9.80	9.93	0.56	0.13
インドルピー: Rupee	1.62	1.72	1.73	0.11	0.01
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	12.72	13.10	13.15	0.43	0.05
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	78.76	80.70	81.26	2.50	0.56
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	―	86.20	86.01	―	△ 0.19

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2017	対11/7予想 Change from forecast anounced Nov. 2017
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	1,698	533
うち宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Net sales of Takara Shuzo International Group	1,151	416
海外酒類事業 Overseas Alcoholic beverages business	147	71
海外日本食材卸事業 Japanese food wholesale business in overseas markets	1,045	353
その他 Other	―	―
連結消去 Elimination	△ 41	△ 9
うちタカラバイオグループ Net sales of Takara Bio Group	549	119
研究用試薬 Research reagents	506	108
理化学機器 Scientific instruments	16	3
受託・その他 Contracted service and other	26	7
バイオ産業支援 計 Bioindustry	549	119
遺伝子医療 Gene Therapy	―	―
医食品バイオ AgriBio	―	―

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	平成29年3月期 実績 FY2017 Actual			平成30年3月期 実績 FY2018 Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo Co., Ltd.	149,452	―	―	149,839	―	―
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group	37,540	37,272	99.3%	70,717	70,420	99.6%
タカラバイオグループ Takara Bio Group	29,375	14,813	50.4%	32,312	18,046	55.8%
その他および調整額 Other / Adjustment	17,824	―	―	15,271	―	―
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	234,193	52,086	22.2%	268,142	88,466	33.0%

③ 海外主要子会社の業績 :Financial Forecast of major overseas subsidiaries

		平成29年3月期 実績 FY2017 Actual		平成30年3月期 実績 FY2018 Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	32,782	4,750	33,946	5,277
Takara Sake USA Inc.	百 万 円 :Millions of Yen	3,567	516	3,807	592
宝酒造食品	千 元 :Thousands of Yuan	46,997	2,404	51,683	1,821
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	768	39	858	30
トマーチン	千 ポ ン ド :Thousands of Pound	14,509	3,364	18,080	3,889
The Tomatin Distillery Co.,Ltd	百 万 円 :Millions of Yen	2,142	496	2,612	562
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	20,479	7,774	22,245	9,091
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	2,228	845	2,495	1,019
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	133,913	15,764	149,220	17,149
FOODEX Group	百 万 円 :Millions of Yen	16,109	1,896	18,906	2,172
タザキフーズ	千 ポ ン ド :Thousands of Pound	34,481	1,995	36,815	1,173
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	5,090	294	5,319	169
ミューチャルトレーディング	千 US ドル :Thousands of US dollar	70,919	3,596	302,485	12,121
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	7,762	393	33,929	1,359
ニッポンフード	千 AUS ドル :Thousands of Australian dollar	―	―	45,618	387
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	―	―	3,923	33
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S.	千 ユ ー ロ :Thousands of Euro	19,372	2,299	21,633	1,935
Takara Bio Europe S.A.S.	百 万 円 :Millions of Yen	2,330	276	2,740	245
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟAB	千 SEK :Thousands of Sweden Krona	28,009	Δ 15,329	38,911	Δ 5,713
Takara Bio Europe AB	百 万 円 :Millions of Yen	356	Δ 194	511	Δ 75
宝生物工程(大連)	千 元 :Thousands of Yuan	305,664	124,340	217,406	53,242
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	5,000	2,034	3,613	884
宝日医生物技術(北京)	千 元 :Thousands of Yuan	135,179	3,737	327,831	39,433
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	2,211	61	5,448	655
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	8,921	1,250	10,051	1,493
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	835	117	998	148
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	196,570	Δ 581	194,345	Δ 8,652
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	318	Δ 0	336	Δ 14
タカラバイオUSA	千 US ドル :Thousands of US dollar	75,697	16,996	95,620	10,009
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	8,236	1,849	10,725	1,122

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo Co., Ltd.

(百万円 :Millions of Yen)

	対前期増減 Change from FY2017			対11/7予想増減 Change from forecast anounced Nov. 2017		
	増減計 Total Change	数量差 Change in quantities	単価差 Change in unit price	増減計 Total Change	数量差 Change in quantities	単価差 Change in unit price
売上総利益 計 Gross profit	Δ 16	+626	Δ 642	Δ 1,341	Δ 1,092	Δ 249
(主な内訳)						
焼酎 Shochu	Δ 969	Δ 934	Δ 34			
清酒 Sake	Δ 395	Δ 24	Δ 371			
ｿﾌﾄｱﾙｺｰﾙ飲料 Light-alcohol refreshers	+1,494	+1,697	Δ 202			
本みりん Hon Mirin	Δ 231	Δ 177	Δ 54			
(参考)原価コストダウン Reference :Cost reduction	Δ 85	※上記数量差および単価差に含む *Included in changes above		Δ 179	※上記数量差および単価差に含む *Included in changes above	

※利益の増加要因を「+」、減少要因を「△」で表示
*An increasing factor and a decreasing factor on profit are shown「+」and「△」, respectively

⑤ 宝ホールディングス(連結)要約損益計算書(p.1)における「その他」の内訳
Breakdown of "Other" segment in the Consolidated Statemnets of Income of Takara Holdings Inc. (Summary) (p.1)

	平成29年3月期 実績 FY2017 Actual		平成30年3月期 実績 FY2018 Actual	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	19,318	951	16,678	942
宝ヘルスケア Takara Healthcare	1,766	12	1,554	68
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	461	389	467	393
その他 Other	17,470	813	17,710	913
「その他」計 Total "Other"	39,017	2,167	36,412	2,318

7. 平成31年3月期 業績予想 :Financial forecast for the year ending March 31, 2019

① 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	平成30年3月期 通期 実績 FY2018 Actual (a)	平成31年3月期 通期 予想 FY2019 Forecast (b)	対前期 Change from FY2018 増減 Change (b-a)	対前期 Change from FY2018 比 % (b/a)	平成30年3月期 第2四半期累計 実績 FY2018(1Q-2Q) Actual (c)	平成31年3月期 第2四半期累計 予想 FY2019(1Q-2Q) Forecast (d)	対前期 Change from FY2018(1Q-2Q) 増減 Change (d-c)	対前期 Change from FY2018(1Q-2Q) 比 % (d/c)
宝酒造 Takara Shuzo Group	149,839	154,000	4,160	102.8%	71,973	73,000	1,026	101.4%
宝酒造インターナショナルグループ Takara Shuzo International Group	70,717	78,000	7,282	110.3%	33,822	37,000	3,177	109.4%
タカラバイオ グループ Takara Bio Group	32,312	36,800	4,487	113.9%	14,126	17,755	3,628	125.7%
その他 Other	36,412	34,000	△ 2,412	93.4%	19,246	16,000	△ 3,246	83.1%
調整額 Adjustment	△ 21,140	△ 20,800	340	―	△ 10,312	△ 8,755	1,557	―
売上高 Net sales	268,142	282,000	13,857	105.2%	128,855	135,000	6,144	104.8%
売上原価 Cost of sales	163,529	170,500	6,970	104.3%	79,401	81,800	2,398	103.0%
売上総利益 Gross profit	104,612	111,500	6,887	106.6%	49,454	53,200	3,745	107.6%
運送費、保管料 Transportation and storage	9,665	10,400	734	107.6%	4,639	5,000	360	107.8%
広告宣伝費 Advertising	3,073	3,100	26	100.9%	1,481	1,500	18	101.3%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	33,688	34,600	911	102.7%	16,328	16,600	271	101.7%
研究開発費 Research and development	5,063	5,700	636	112.6%	2,505	2,900	394	115.7%
管理費、その他 Other, net	37,508	40,400	2,891	107.7%	18,371	19,700	1,328	107.2%
販売費及び一般管理費 SG&A expenses	88,999	94,200	5,200	105.8%	43,326	45,700	2,373	105.5%
宝酒造 Takara Shuzo Group	5,569	6,100	530	109.5%	1,991	2,000	8	100.4%
宝酒造インターナショナルグループ Takara Shuzo International Group	4,393	4,900	506	111.5%	2,223	2,300	76	103.4%
タカラバイオ グループ Takara Bio Group	3,555	5,000	1,444	140.6%	688	2,500	1,811	363.1%
その他 Other	2,318	2,000	△ 318	86.3%	1,371	900	△ 471	65.6%
調整額 Adjustment	△ 224	△ 700	△ 475	―	△ 147	△ 200	△ 53	―
営業利益(△:損失) Operating income(Δ:loss)	15,612	17,300	1,687	110.8%	6,128	7,500	1,371	122.4%
受取利息・配当金 Interest and Dividends income	700	600	△ 100	85.6%	373	300	△ 73	80.3%
その他営業外収益 Other, net	707	400	△ 307	56.5%	301	200	△ 101	66.3%
営業外収益 Non-operating income	1,408	1,000	△ 408	71.0%	675	500	△ 175	74.0%
支払利息 Interest and discounts expenses	568	300	△ 268	52.7%	325	100	△ 225	30.7%
その他営業外費用 Other, net	367	100	△ 267	27.2%	276	100	△ 176	36.1%
営業外費用 Non-operating expenses	936	400	△ 536	42.7%	602	200	△ 402	33.2%
経常利益(△:損失) Ordinary income(Δ:loss)	16,084	17,900	1,815	111.3%	6,200	7,800	1,599	125.8%
特別利益 Extraordinary gain	3,499	―	△ 3,499	―	173	―	△ 173	―
特別損失 Extraordinary loss	679	900	220	132.4%	61	200	138	327.7%
税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes	18,903	17,000	△ 1,903	89.9%	6,313	7,600	1,286	120.4%
法人税、住民税及び事業税 Current income taxes	6,859	5,500	△ 874	86.3%	2,351	2,400	△ 59	97.6%
法人税等調整額 Deferred income taxes	△ 484				108			
当期純利益(△:損失) Net income(Δ:loss)	12,528	11,500	△ 1,028	91.8%	3,853	5,200	1,346	134.9%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	1,499	1,900	400	126.7%	405	1,000	594	246.4%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent	11,029	9,600	△ 1,429	87.0%	3,447	4,200	752	121.8%
設備投資額(有形・無形) Capital expenditures	6,414	14,900	8,485	232.3%	2,451			
減価償却費(有形・無形) Depreciation and Amortization	6,430	6,900	469	107.3%	3,157	3,300	142	104.5%
のれん償却額 Amortization of goodwill	843	870	26	103.2%	407	430	22	105.5%

② 宝酒造 :Takara Shuzo Co., Ltd.

（百万円 :Millions of Yen）

	平成30年3月期 通期 実績 FY2018 Actual (a)	平成31年3月期 通期 予想 FY2019 Forecast (b)	対前期 Change from FY2018 増減 Change (b-a)	対前期 Change from FY2018 比 % (b/a)	平成30年3月期 第2四半期累計 実績 FY2018(1Q-2Q) Actual (c)	平成31年3月期 第2四半期累計 予想 FY2019(1Q-2Q) Forecast (d)	対前期 Change from FY2018(1Q-2Q) 増減 Change (d-c)	対前期 Change from FY2018(1Q-2Q) 比 % (d/c)
焼酎 Shochu	55,034	53,800	△ 1,234	97.8%	27,449	26,300	△ 1,149	95.8%
清酒 Sake	22,222	23,600	1,377	106.2%	8,619	9,400	780	109.1%
ソフトアルコール飲料 Light-alcohol refreshers	34,267	38,600	4,332	112.6%	17,489	19,300	1,810	110.4%
その他酒類 Other liquors	6,639	5,600	△ 1,039	84.3%	3,160	2,600	△ 560	82.3%
本みりん Hon Mirin	14,063	14,000	△ 63	99.5%	6,735	6,600	△ 135	98.0%
その他調味料 Other seasonings	9,760	10,000	239	102.5%	4,703	4,800	96	102.1%
原料用アルコール等 Raw alcohol	7,852	8,400	547	107.0%	3,814	4,000	185	104.9%
売上高 Net sales	149,839	154,000	4,160	102.8%	71,973	73,000	1,026	101.4%
売上原価 Cost of sales	89,681	92,000	2,318	102.6%	43,360	44,000	639	101.5%
売上総利益 Gross profit	60,158	62,000	1,841	103.1%	28,613	29,000	386	101.4%
運送費、保管料 Transportation and storage	7,251	7,600	348	104.8%	3,493	3,600	106	103.1%
広告宣伝費 Advertising	2,601	2,600	△ 1	99.9%	1,210	1,300	89	107.4%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	32,342	33,000	657	102.0%	15,707	15,800	92	100.6%
研究開発費 Research and development	370	400	29	108.0%	182	200	17	109.3%
管理費、その他 Other, net	12,023	12,300	276	102.3%	6,027	6,100	72	101.2%
販売費及び一般管理費 SG&A expenses	54,589	55,900	1,310	102.4%	26,621	27,000	378	101.4%
営業利益（△：損失） Operating income(Δ:loss)	5,569	6,100	530	109.5%	1,991	2,000	8	100.4%
営業外収益 Non-operating income	1,369	700	△ 669	51.1%	1,252	700	△ 552	55.9%
営業外費用 Non-operating expenses	256	200	△ 56	78.0%	110	100	△ 10	90.7%
経常利益（△：損失） Ordinary income(Δ:loss)	6,681	6,600	△ 81	98.8%	3,133	2,600	△ 533	83.0%
特別利益 Extraordinary gain	4,711	—	△ 4,711	—	—	—	—	—
特別損失 Extraordinary loss	150	200	49	132.7%	41	100	58	242.0%
税金等調整前当期純利益（△：損失） Income(Δ:loss) before income taxes	11,243	6,400	△ 4,843	56.9%	3,091	2,500	△ 591	80.9%
法人税等 Current income taxes, etc.	2,887	2,000	△ 910	68.7%	502	700	17	102.6%
法人税等調整額 Deferred income taxes	22				179			
当期純利益（△：損失） Net income(Δ:loss)	8,332	4,400	△ 3,932	52.8%	2,409	1,800	△ 609	74.7%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	—	—	—	—	—	—	—	—
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent	8,332	4,400	△ 3,932	52.8%	2,409	1,800	△ 609	74.7%
設備投資額（有形・無形） Capital expenditures	2,696	3,700	1,003	137.2%	1,002			
減価償却費（有形・無形） Depreciation and Amortization	2,225	2,500	274	112.3%	1,059	1,200	140	113.3%

③ 宝酒造インターナショナルグループ :Takara Shuzo International Group

（百万円 :Millions of Yen）

	平成30年3月期 通期 実績 FY2018 Actual (a)	平成31年3月期 通期 予想 FY2019 Forecast (b)	対前期 Change from FY2018 増減 Change (b-a)	対前期 Change from FY2018 比 % (b/a)	平成30年3月期 第2四半期累計 実績 FY2018(1Q-2Q) Actual (c)	平成31年3月期 第2四半期累計 予想 FY2019(1Q-2Q) Forecast (d)	対前期 Change from FY2018(1Q-2Q) 増減 Change (d-c)	対前期 Change from FY2018(1Q-2Q) 比 % (d/c)
海外酒類事業 Overseas Alcoholic beverages business	10,483	10,800	316	103.0%	5,055	5,100	44	100.9%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	62,079	69,500	7,420	112.0%	29,694	33,200	3,505	111.8%
共通 Eliminations/Corporate	49	100	50	201.7%	21	50	28	231.7%
連結消去 Elimination	△ 1,895	△ 2,400	△ 504	—	△ 949	△ 1,350	△ 400	—
売上高 Net sales	70,717	78,000	7,282	110.3%	33,822	37,000	3,177	109.4%
売上原価 Cost of sales	49,843	54,700	4,856	109.7%	23,845	25,900	2,054	108.6%
売上総利益 Gross profit	20,874	23,300	2,425	111.6%	9,976	11,100	1,123	111.3%
運送費、保管料 Transportation and storage	1,921	2,300	378	119.7%	912	1,100	187	120.6%
広告宣伝費 Advertising	89	100	10	111.5%	31	100	68	317.0%
販売促進費 Sales promotion	640	700	59	109.3%	251	300	48	119.2%
管理費、その他 Other, net	13,829	15,300	1,470	110.6%	6,557	7,300	742	111.3%
販売費及び一般管理費 SG&A expenses	16,480	18,400	1,919	111.6%	7,753	8,800	1,046	113.5%
海外酒類事業 Overseas Alcoholic beverages business	1,972	2,000	27	101.4%	959	900	△ 59	93.8%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	3,735	4,700	964	125.8%	1,839	2,200	360	119.6%
共通 Eliminations/Corporate	△ 828	△ 1,300	△ 471	—	△ 341	△ 500	△ 158	—
連結消去 Elimination	△ 485	△ 500	△ 14	—	△ 233	△ 300	△ 66	—
営業利益（△：損失） Operating income(Δ:loss)	4,393	4,900	506	111.5%	2,223	2,300	76	103.4%
営業外収益 Non-operating income	204	200	△ 4	97.6%	133	—	△ 133	—
営業外費用 Non-operating expenses	268	100	△ 168	37.3%	157	100	△ 57	63.3%
経常利益（△：損失） Ordinary income(Δ:loss)	4,330	5,000	669	115.5%	2,199	2,200	0	100.0%
特別利益 Extraordinary gain	4	—	△ 4	—	4	—	△ 4	—
特別損失 Extraordinary loss	18	—	△ 18	—	0	—	△ 0	—
税金等調整前当期純利益（△：損失） Income(Δ:loss) before income taxes	4,316	5,000	683	115.8%	2,202	2,200	△ 2	99.9%
法人税等 Current income taxes, etc.	1,913	1,600	96	106.4%	888	700	△ 145	82.8%
法人税等調整額 Deferred income taxes	△ 409				△ 43			
当期純利益（△：損失） Net income(Δ:loss)	2,812	3,400	587	120.9%	1,357	1,500	142	110.5%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	581	600	18	103.2%	294	200	△ 94	67.9%
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent	2,230	2,800	569	125.5%	1,062	1,300	237	122.3%
設備投資額（有形・無形） Capital expenditures	1,677	3,570	1,892	212.8%	774			
減価償却費（有形・無形） Depreciation and Amortization	938	1,000	61	106.5%	455	500	44	109.7%
のれん償却額 Amortization of goodwill	353	360	6	101.8%	170	180	9	105.4%

④ タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

	平成30年3月期 通期 実績 FY2018 Actual (a)	平成31年3月期 通期 予想 FY2019 Forecast (b)	対前期 Change from FY2018 増減 Change (b-a)	対前期 Change from FY2018 比 % (b/a)	平成30年3月期 第2四半期累計 実績 FY2018(1Q-2Q) Actual (c)	平成31年3月期 第2四半期累計 予想 FY2019(1Q-2Q) Forecast (d)	対前期 Change from FY2018(1Q-2Q) 増減 Change (d-c)	対前期 Change from FY2018(1Q-2Q) 比 % (d/c)
研究用試薬 Research reagents	22,207	24,071	1,864	108.4%	10,000	11,513	1,512	115.1%
理化学機器 Scientific instruments	2,635	3,262	627	123.8%	1,306	1,518	212	116.3%
受託・その他ファイン Contracted service and other	4,725	5,384	659	113.9%	1,807	1,932	125	106.9%
バイオ産業支援　計 Bioindustry	29,568	32,719	3,150	110.7%	13,114	14,964	1,850	114.1%
遺伝子医療 Gene Therapy	500	1,860	1,360	372.1%	―	1,800	1,800	―
医食品バイオ AgriBio	2,243	2,219	△ 23	98.9%	1,012	991	△ 21	97.9%
売上高 Net sales	32,312	36,800	4,487	113.9%	14,126	17,755	3,628	125.7%
売上原価 Cost of sales	13,657	15,122	1,464	110.7%	5,965	6,914	948	115.9%
売上総利益 Gross profit	18,655	21,677	3,022	116.2%	8,160	10,840	2,680	132.8%
運送費、保管料 Transportation and storage	643	758	115	117.9%	303	368	65	121.5%
広告宣伝費 Advertising	83	93	10	112.9%	39	47	7	118.7%
販売促進費 Sales promotion	729	812	83	111.5%	394	392	△ 2	99.5%
研究開発費 Research and development	4,653	5,229	576	112.4%	2,297	2,681	383	116.7%
管理費、その他 Other, net	8,990	9,782	792	108.8%	4,435	4,849	413	109.3%
販売費及び一般管理費 SG&A expenses	15,099	16,677	1,577	110.5%	7,471	8,339	868	111.6%
バイオ産業支援 Bioindustry	6,683	7,523	839	112.6%	2,473	2,997	524	121.2%
遺伝子医療 Gene Therapy	△ 1,322	△ 309	1,013	―	△ 850	555	1,406	―
医食品バイオ AgriBio	107	98	△ 8	92.3%	△ 2	―	2	―
共通 Eliminations/Corporate	△ 1,912	△ 2,312	△ 400	―	△ 930	△ 1,052	△ 121	―
営業利益（△：損失） Operating income(Δ:loss)	3,555	5,000	1,444	140.6%	688	2,500	1,811	363.1%
営業外収益 Non-operating income	402	257	△ 145	64.0%	129	89	△ 40	69.1%
営業外費用 Non-operating expenses	96	57	△ 38	59.7%	52	33	△ 19	62.7%
経常利益（△：損失） Ordinary income(Δ:loss)	3,861	5,200	1,338	134.6%	766	2,557	1,791	333.8%
特別利益 Extraordinary gain	0	―	△ 0	―	0	―	△ 0	―
特別損失 Extraordinary loss	501	555	53	110.7%	16	150	134	901.5%
税金等調整前当期純利益（△：損失） Income(Δ:loss) before income taxes	3,361	4,644	1,283	138.2%	749	2,406	1,657	321.1%
法人税等 Current income taxes, etc.	1,155	1,529	506	149.5%	406	760	310	168.9%
法人税等調整額 Deferred income taxes	△ 132				43			
当期純利益（△：損失） Net income(Δ:loss)	2,338	3,115	777	133.3%	299	1,646	1,346	550.0%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	3	15	12	514.0%	△ 3	△ 0	2	―
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent	2,335	3,100	764	132.8%	302	1,646	1,344	544.1%
設備投資額（有形・無形） Capital expenditures	1,539	7,103	5,564	461.4%	439			
減価償却費（有形・無形） Depreciation and Amortization	2,568	2,828	259	110.1%	1,247	1,392	145	111.6%
のれん償却額 Amortization of goodwill	489	510	21	104.3%	236	255	18	107.8%

8. 平成31年3月期 参考資料 :Reference Data for the year ending March 31, 2019

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	平成30年3月期 FY2018	平成31年3月期 FY2019 / Apr. 1, 2018 - Mar. 31, 2019	
	実績 Actual (a)	予想 Forecast (b)	前期差 Change(b-a)
米ドル : US dollar	112.17	111.00	Δ 1.17
ポンド: Pound	144.50	146.00	1.50
ユーロ: Euro	126.70	131.00	4.30
人民元: Yuan	16.62	16.40	Δ 0.22
100ウォン: 100 Won	9.93	9.80	Δ 0.13
インドルピー: Rupee	1.73	1.70	Δ 0.03
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	13.15	13.80	0.65
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	81.26	81.60	0.34
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	86.01	87.80	1.79

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2018
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	365
宝酒造インターナショナルｸﾞﾙｰﾌﾟ計 Net sales of Takara Shuzo International Group	433
海外酒類事業 Overseas Alcoholic beverages business	Δ 55
海外日本食材卸事業 Japanese food wholesale business in overseas markets	472
その他 Other	―
連結消去 Elimination	16
タカラバイオグループ 計 Net sales of Takara Bio Group	Δ 69
研究用試薬 Research reagents	Δ 73
理化学機器 Scientific instruments	3
受託・その他 Contracted service and other	Δ 0
バイオ産業支援 計 Bioindustry	Δ 69
遺伝子医療 Gene Therapy	―
医食品バイオ AgriBio	―

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	平成30年3月期通期実績 FY2018 Actual			平成31年3月期通期予想 FY2019 Forecast		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo Co., Ltd.	149,839	―	―	154,000	―	―
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group	70,717	70,420	99.6%	78,000	78,000	100.0%
タカラバイオグループ Takara Bio Group	32,312	18,046	55.8%	36,800	20,494	55.7%
その他および調整額 Other / Adjustment	15,271	―	―	13,200	―	―
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	268,142	88,466	33.0%	282,000	98,494	34.9%

③ 海外主要子会社の業績 :Financial Forecast of major overseas subsidiaries

		平成30年3月期 実績 FY2018 Actual		平成31年3月期 予想 FY2019 Forecast	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	33,946	5,277	36,273	5,502
Takara Sake USA Inc.	百 万 円 :Millions of Yen	3,807	592	4,026	610
宝酒造食品	千 元 :Thousands of Yuan	51,683	1,821	54,782	2,628
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	858	30	898	43
トマーチン	千 ポ ン ド :Thousands of Pound	18,080	3,889	17,175	4,022
The Tomatin Distillery Co.,Ltd	百 万 円 :Millions of Yen	2,612	562	2,507	587
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	22,245	9,091	23,113	9,188
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	2,495	1,019	2,565	1,019
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	149,220	17,149	165,133	19,370
FOODEX Group	百 万 円 :Millions of Yen	18,906	2,172	21,632	2,537
タザキフーズ	千 ポ ン ド :Thousands of Pound	36,815	1,173	39,600	2,204
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	5,319	169	5,781	321
ミューチャルトレーディング	千 US ドル :Thousands of US dollar	302,485	12,121	337,415	16,015
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	33,929	1,359	37,453	1,777
ニッポンフード	千 AUS ドル :Thousands of Australian dollar	45,618	387	54,750	1,316
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	3,923	33	4,807	115
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S.	千 ユ ー ロ :Thousands of Euro	21,633	1,935	26,703	3,434
Takara Bio Europe S.A.S.	百 万 円 :Millions of Yen	2,740	245	3,498	449
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟAB	千 SEK :Thousands of Sweden Krona	38,911	Δ 5,713	52,213	Δ 8,198
Takara Bio Europe AB	百 万 円 :Millions of Yen	511	Δ 75	720	Δ 113
宝生物工程(大連)	千 元 :Thousands of Yuan	217,406	53,242	228,534	55,259
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	3,613	884	3,747	906
宝日医生物技術(北京)	千 元 :Thousands of Yuan	327,831	39,433	359,019	50,028
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	5,448	655	5,887	820
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	10,051	1,493	10,590	1,592
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	998	148	1,037	156
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	194,345	Δ 8,652	229,490	10,186
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	336	Δ 14	390	17
タカラバイオUSA	千 US ドル :Thousands of US dollar	95,620	10,009	108,030	13,695
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	10,725	1,122	11,991	1,520

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo Co., Ltd.

(百万円 :Millions of Yen)

	対前期増減 Change from FY2018		
	増減計 Total Change	数量差 Change in quantities	単価差 Change in unit price
売上総利益 計 Gross profit	+1,841	+2,265	Δ 423
(主な内訳)			
焼酎 Shochu	Δ 594	Δ 458	Δ 135
清酒 Sake	+382	+755	Δ 373
ソフトアルコール飲料 Light-alcohol refreshers	+2,154	+1,966	+188
本みりん Hon Mirin	Δ 45	+33	Δ 78
(参考)原価コストダウン Reference :Cost reduction	Δ 144	※上記数量差および単価差に含む *Included in changes above	

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)業績予想(p.10)における「その他」の内訳 :Breakdown of "Other" segment in the Financial forecast of Takara Holdings Inc. (p.10)

	平成30年3月期 実績 FY2018 Actual		平成31年3月期 予想 FY2019 Forecast	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	16,678	942	14,385	564
宝ヘルスケア Takara Healthcare	1,554	68	1,545	125
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	467	393	535	442
その他 Other	17,710	913	17,533	868
「その他」計 Total "Other"	36,412	2,318	34,000	2,000